

Table 1: Effect of Vehicle Exposure on Non-neoplasm Incidence in Females

		Vehicle Controls	Naïve Controls
Liver * Fibrosis	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	86 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	---	0 1 0 0
	JT/SW P-Value	0.159	0.159
Liver * Hepatodiaphragmatic Nodule	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	86 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	---	0 1 0 0
	JT/SW P-Value	0.159	0.159
Liver * Granuloma	Simple Incidence	2/20 (10.0%)	0/20 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	0/20.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	0/20 (0.0%)
	Time-to-First	90 (T)	----
	Poly-K P-Value	0.234N	0.234N
	Severity Profile	2 0 0 0	---
	JT/SW P-Value	0.076N	0.076N
Pancreas, Acinar Cell * Atrophy	Simple Incidence	4/20 (20.0%)	8/20 (40.0%)
	Poly-K Incidence	4/20.0 (20.0%)	8/20.0 (40.0%)
	Terminal Incidence	4/20 (20.0%)	8/20 (40.0%)
	Time-to-First	85 (T)	85 (T)
	Poly-K P-Value	0.151	0.151
	Severity Profile	2 2 0 0	6 2 0 0
	JT/SW P-Value	0.113	0.113
Pancreas * Inflammation	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	87 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	---	1 0 0 0
	JT/SW P-Value	0.159	0.159
Pituitary Gland * Cyst	Simple Incidence	1/20 (5.0%)	1/20 (5.0%)
	Poly-K Incidence	1/20.0 (5.0%)	1/20.0 (5.0%)
	Terminal Incidence	1/20 (5.0%)	1/20 (5.0%)
	Time-to-First	88 (T)	93 (T)
	Poly-K P-Value	0.760	0.760
	Severity Profile	---	---
	JT/SW P-Value	0.249	0.249
Thyroid Gland * Ultimobranchial Cyst	Simple Incidence	6/20 (30.0%)	7/20 (35.0%)
	Poly-K Incidence	6/20.0 (30.0%)	7/20.0 (35.0%)
	Terminal Incidence	6/20 (30.0%)	7/20 (35.0%)
	Time-to-First	85 (T)	85 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	---	---
	JT/SW P-Value	0.159	0.159

Table 1: Effect of Vehicle Exposure on Non-neoplasm Incidence in Females

		Vehicle Controls	Naïve Controls
Thyroid Gland * Ectopic Thymus	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	86 (T)
	Poly-K P-Value	0.500	0.500
Adrenal Cortex * Accessory Adrenal Cortical Nodule	Simple Incidence	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	----	88 (T)
	Poly-K P-Value	0.234	0.234
Ovary * Cyst	Simple Incidence	4/20 (20.0%)	5/20 (25.0%)
	Poly-K Incidence	4/20.0 (20.0%)	5/20.0 (25.0%)
	Terminal Incidence	4/20 (20.0%)	5/20 (25.0%)
	Time-to-First	85 (T)	86 (T)
	Poly-K P-Value	0.500	0.500
Ovary, Follicle * Cyst	Simple Incidence	4/20 (20.0%)	2/20 (10.0%)
	Poly-K Incidence	4/20.0 (20.0%)	2/20.0 (10.0%)
	Terminal Incidence	4/20 (20.0%)	2/20 (10.0%)
	Time-to-First	85 (T)	93 (T)
	Poly-K P-Value	0.331N	0.331N
	Severity Profile	0 4 0 0	0 2 0 0
	JT/SW P-Value	0.191N	0.191N
	RTE P-Value	0.212N	0.212N
Ovary, Rete Ovarii * Cyst	Simple Incidence	1/20 (5.0%)	3/20 (15.0%)
	Poly-K Incidence	1/20.0 (5.0%)	3/20.0 (15.0%)
	Terminal Incidence	1/20 (5.0%)	3/20 (15.0%)
	Time-to-First	95 (T)	86 (T)
	Poly-K P-Value	0.301	0.301
Ovary, Corpus Luteum * Hypertrophy	Simple Incidence	4/20 (20.0%)	2/20 (10.0%)
	Poly-K Incidence	4/20.0 (20.0%)	2/20.0 (10.0%)
	Terminal Incidence	4/20 (20.0%)	2/20 (10.0%)
	Time-to-First	85 (T)	93 (T)
	Poly-K P-Value	0.331N	0.331N
Ovary, Antral Follicles * Depletion	Simple Incidence	3/20 (15.0%)	1/20 (5.0%)
	Poly-K Incidence	3/20.0 (15.0%)	1/20.0 (5.0%)
	Terminal Incidence	3/20 (15.0%)	1/20 (5.0%)
	Time-to-First	85 (T)	93 (T)
	Poly-K P-Value	0.301N	0.301N
Uterus, Endometrium * Vacuolization Cytoplasmic	Simple Incidence	3/20 (15.0%)	2/20 (10.0%)
	Poly-K Incidence	3/20.0 (15.0%)	2/20.0 (10.0%)
	Terminal Incidence	3/20 (15.0%)	2/20 (10.0%)
	Time-to-First	85 (T)	93 (T)
	Poly-K P-Value	0.500N	0.500N

Table 1: Effect of Vehicle Exposure on Non-neoplasm Incidence in Females

		Vehicle Controls	Naïve Controls
Uterus, Endometrium * Hyperplasia	Simple Incidence	1/20 (5.0%)	0/20 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/20.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)
	Time-to-First	88 (T)	----
	Poly-K P-Value	0.500N	0.500N
	Severity Profile	0 1 0 0	---
	JT/SW P-Value	0.159N	0.159N
Uterus, Endometrium * Metaplasia	RTE P-Value	0.245N	0.245N
	Simple Incidence	1/20 (5.0%)	2/20 (10.0%)
	Poly-K Incidence	1/20.0 (5.0%)	2/20.0 (10.0%)
	Terminal Incidence	1/20 (5.0%)	2/20 (10.0%)
	Time-to-First	88 (T)	87 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	1 0 0 0	2 0 0 0
Vagina, Mucocyte * Hyperplasia	JT/SW P-Value	0.277	0.277
	RTE P-Value	0.280	0.280
	Simple Incidence	3/20 (15.0%)	2/20 (10.0%)
	Poly-K Incidence	3/20.0 (15.0%)	2/20.0 (10.0%)
	Terminal Incidence	3/20 (15.0%)	2/20 (10.0%)
	Time-to-First	85 (T)	93 (T)
	Poly-K P-Value	0.500N	0.500N
Mammary Gland, Duct * Hyperplasia	Simple Incidence	7/20 (35.0%)	9/20 (45.0%)
	Poly-K Incidence	7/20.0 (35.0%)	9/20.0 (45.0%)
	Terminal Incidence	7/20 (35.0%)	9/20 (45.0%)
	Time-to-First	85 (T)	86 (T)
	Poly-K P-Value	0.376	0.376
	Severity Profile	7 0 0 0	7 2 0 0
	JT/SW P-Value	0.198	0.198
Mammary Gland, Alveolus * Hyperplasia	RTE P-Value	0.196	0.196
	Simple Incidence	6/20 (30.0%)	4/20 (20.0%)
	Poly-K Incidence	6/20.0 (30.0%)	4/20.0 (20.0%)
	Terminal Incidence	6/20 (30.0%)	4/20 (20.0%)
	Time-to-First	85 (T)	87 (T)
	Poly-K P-Value	0.360N	0.360N
	Severity Profile	5 1 0 0	1 3 0 0
Mammary Gland, Alveolus * Hyperplasia (adjusted for pseudo- pregnancy)	JT/SW P-Value	0.321N	0.321N
	RTE P-Value	0.324N	0.324N
	Simple Incidence	5/17 (29.4%)	2/18 (11.1%)
	Poly-K Incidence	5/17.0 (29.4%)	2/18.0 (11.1%)
	Terminal Incidence	5/17 (29.4%)	2/18 (11.1%)
	Time-to-First	85 (T)	87 (T)
	Poly-K P-Value	0.177N	0.177N
	Severity Profile	4 1 0 0	1 1 0 0
	JT/SW P-Value	0.105N	0.105N
	RTE P-Value	0.142N	0.142N

Table 1: Effect of Vehicle Exposure on Non-neoplasm Incidence in Females

		Vehicle Controls	Naïve Controls
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	11/20 (55.0%)	9/20 (45.0%)
	Poly-K Incidence	11/20.0 (55.0%)	9/20.0 (45.0%)
	Terminal Incidence	11/20 (55.0%)	9/20 (45.0%)
	Time-to-First	85 (T)	86 (T)
	Poly-K P-Value	0.378N	0.378N
	Severity Profile	10 1 0 0	5 4 0 0
	JT/SW P-Value	0.470N	0.470N
Mammary Gland, Duct or Alveolus * Hyperplasia (adjusted for pseudo-pregnancy)	Simple Incidence	11/19 (57.9%)	9/20 (45.0%)
	Poly-K Incidence	11/19.0 (57.9%)	9/20.0 (45.0%)
	Terminal Incidence	11/19 (57.9%)	9/20 (45.0%)
	Time-to-First	85 (T)	86 (T)
	Poly-K P-Value	0.317N	0.317N
	Severity Profile	10 1 0 0	5 4 0 0
	JT/SW P-Value	0.414N	0.414N
Kidney, Renal Tubule * Mineralization	Simple Incidence	14/20 (70.0%)	14/20 (70.0%)
	Poly-K Incidence	14/20.0 (70.0%)	14/20.0 (70.0%)
	Terminal Incidence	14/20 (70.0%)	14/20 (70.0%)
	Time-to-First	85 (T)	85 (T)
	Poly-K P-Value	0.632	0.632
	Severity Profile	11 3 0 0	13 1 0 0
	JT/SW P-Value	0.332N	0.332N
Kidney * Cyst	Simple Incidence	1/20 (5.0%)	6/20 (30.0%)
	Poly-K Incidence	1/20.0 (5.0%)	6/20.0 (30.0%)
	Terminal Incidence	1/20 (5.0%)	6/20 (30.0%)
	Time-to-First	88 (T)	85 (T)
	Poly-K P-Value	0.043 *	0.043 *
	Severity Profile	1 0 0 0	6 0 0 0
	JT/SW P-Value	0.020 *	0.020 *
Kidney, Renal Tubule * Cyst	Simple Incidence	1/20 (5.0%)	5/20 (25.0%)
	Poly-K Incidence	1/20.0 (5.0%)	5/20.0 (25.0%)
	Terminal Incidence	1/20 (5.0%)	5/20 (25.0%)
	Time-to-First	88 (T)	85 (T)
	Poly-K P-Value	0.089	0.089
	Severity Profile	1 0 0 0	5 0 0 0
	JT/SW P-Value	0.040 *	0.040 *
Kidney * Nephropathy	Simple Incidence	12/20 (60.0%)	12/20 (60.0%)
	Poly-K Incidence	12/20.0 (60.0%)	12/20.0 (60.0%)
	Terminal Incidence	12/20 (60.0%)	12/20 (60.0%)
	Time-to-First	85 (T)	86 (T)
	Poly-K P-Value	0.623	0.623
	Severity Profile	12 0 0 0	12 0 0 0
	JT/SW P-Value	0.500	0.500
	RTE P-Value	0.500N	0.500

Table 2: Effect of Vehicle Exposure on Non-neoplasm Incidence in Males

		Vehicle Controls	Naïve Controls
Heart * Cardiomyopathy	Simple Incidence	7/20 (35.0%)	4/20 (20.0%)
	Poly-K Incidence	7/20.0 (35.0%)	4/20.0 (20.0%)
	Terminal Incidence	7/20 (35.0%)	4/20 (20.0%)
	Time-to-First	85 (T)	85 (T)
	Poly-K P-Value	0.242N	0.242N
	Severity Profile	6 1 0 0	4 0 0 0
	JT/SW P-Value	0.133N	0.133N
Liver * Hepatodiaphragmatic Nodule	Simple Incidence	1/20 (5.0%)	4/20 (20.0%)
	Poly-K Incidence	1/20.0 (5.0%)	4/20.0 (20.0%)
	Terminal Incidence	1/20 (5.0%)	4/20 (20.0%)
	Time-to-First	90 (T)	90 (T)
	Poly-K P-Value	0.169	0.169
	Severity Profile		
	JT/SW P-Value		
Pancreas, Acinus * Degeneration	Simple Incidence	4/20 (20.0%)	12/20 (60.0%)
	Poly-K Incidence	4/20.0 (20.0%)	12/20.0 (60.0%)
	Terminal Incidence	4/20 (20.0%)	12/20 (60.0%)
	Time-to-First	90 (T)	86 (T)
	Poly-K P-Value	0.008 **	0.008 **
	Severity Profile	4 0 0 0	8 4 0 0
	JT/SW P-Value	0.003 **	0.003 **
Pancreas * Inflammation	Simple Incidence	2/20 (10.0%)	4/20 (20.0%)
	Poly-K Incidence	2/20.0 (10.0%)	4/20.0 (20.0%)
	Terminal Incidence	2/20 (10.0%)	4/20 (20.0%)
	Time-to-First	90 (T)	90 (T)
	Poly-K P-Value	0.331	0.331
	Severity Profile	2 0 0 0	4 0 0 0
	JT/SW P-Value	0.191	0.191
Pancreas * Infiltration Cellular	Simple Incidence	2/20 (10.0%)	8/20 (40.0%)
	Poly-K Incidence	2/20.0 (10.0%)	8/20.0 (40.0%)
	Terminal Incidence	2/20 (10.0%)	8/20 (40.0%)
	Time-to-First	90 (T)	86 (T)
	Poly-K P-Value	0.029 *	0.029 *
	Severity Profile	2 0 0 0	7 1 0 0
	JT/SW P-Value	0.014 *	0.014 *
Islets, Pancreatic * Fibrosis	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	---	90 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	---	1 0 0 0
	JT/SW P-Value	0.159	0.159
	RTE P-Value	0.252	0.252

Table 2: Effect of Vehicle Exposure on Non-neoplasm Incidence in Males

		Vehicle Controls	Naïve Controls
Pituitary Gland * Cyst	Simple Incidence	3/20 (15.0%)	3/20 (15.0%)
	Poly-K Incidence	3/20.0 (15.0%)	3/20.0 (15.0%)
	Terminal Incidence	3/20 (15.0%)	3/20 (15.0%)
	Time-to-First	85 (T)	85 (T)
	Poly-K P-Value	0.667	0.667
Thyroid Gland * Ultimobranchial Cyst	Simple Incidence	6/20 (30.0%)	5/20 (25.0%)
	Poly-K Incidence	6/20.0 (30.0%)	5/20.0 (25.0%)
	Terminal Incidence	6/20 (30.0%)	5/20 (25.0%)
	Time-to-First	89 (T)	86 (T)
	Poly-K P-Value	0.500N	0.500N
Mammary Gland, Duct * Hyperplasia	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	89 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	---	1 0 0 0
	JT/SW P-Value	0.159	0.159
	RTE P-Value	0.248	0.248
Mammary Gland, Alveolus * Hyperplasia	Simple Incidence	5/20 (25.0%)	6/20 (30.0%)
	Poly-K Incidence	5/20.0 (25.0%)	6/20.0 (30.0%)
	Terminal Incidence	5/20 (25.0%)	6/20 (30.0%)
	Time-to-First	85 (T)	86 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	4 1 0 0	3 3 0 0
	JT/SW P-Value	0.308	0.308
	RTE P-Value	0.311	0.311
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	5/20 (25.0%)	6/20 (30.0%)
	Poly-K Incidence	5/20.0 (25.0%)	6/20.0 (30.0%)
	Terminal Incidence	5/20 (25.0%)	6/20 (30.0%)
	Time-to-First	85 (T)	86 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	4 1 0 0	3 3 0 0
	JT/SW P-Value	0.308	0.308
	RTE P-Value	0.311	0.311
Lymph Node, Mandibular * Hyperplasia	Simple Incidence	2/20 (10.0%)	0/20 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	0/20.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	0/20 (0.0%)
	Time-to-First	89 (T)	----
	Poly-K P-Value	0.234N	0.234N
	Severity Profile	0 1 0 1	---
	JT/SW P-Value	0.076N	0.076N
	RTE P-Value	0.120N	0.120N

Table 2: Effect of Vehicle Exposure on Non-neoplasm Incidence in Males

		Vehicle Controls	Naïve Controls
Epididymis * Hypospermia	Simple Incidence	1/20 (5.0%)	0/20 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/20.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)
	Time-to-First	89 (T)	----
	Poly-K P-Value	0.500N	0.500N
	Severity Profile	0 0 0 1	---
	JT/SW P-Value	0.159N	0.159N
Epididymis * Exfoliated Germ Cell	Simple Incidence	1/20 (5.0%)	0/20 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/20.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)
	Time-to-First	89 (T)	----
	Poly-K P-Value	0.500N	0.500N
	Severity Profile	1 0 0 0	---
	JT/SW P-Value	0.159N	0.159N
Preputial Gland * Inflammation	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	90 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	---	0 0 0 1
	JT/SW P-Value	0.159	0.159
Preputial Gland, Duct * Ectasia	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	90 (T)
	Poly-K P-Value	0.500	0.500
	Severity Profile	---	0 0 0 1
	JT/SW P-Value	0.159	0.159
Prostate * Inflammation	Simple Incidence	2/20 (10.0%)	4/20 (20.0%)
	Poly-K Incidence	2/20.0 (10.0%)	4/20.0 (20.0%)
	Terminal Incidence	2/20 (10.0%)	4/20 (20.0%)
	Time-to-First	90 (T)	85 (T)
	Poly-K P-Value	0.331	0.331
	Severity Profile	2 0 0 0	3 1 0 0
	JT/SW P-Value	0.180	0.180
Prostate * Infiltration Cellular	Simple Incidence	17/20 (85.0%)	15/20 (75.0%)
	Poly-K Incidence	17/20.0 (85.0%)	15/20.0 (75.0%)
	Terminal Incidence	17/20 (85.0%)	15/20 (75.0%)
	Time-to-First	85 (T)	85 (T)
	Poly-K P-Value	0.349N	0.349N
	Severity Profile	8 7 2 0	7 7 0 1
	JT/SW P-Value	0.265N	0.265N
	RTE P-Value	0.268N	0.268N

Table 2: Effect of Vehicle Exposure on Non-neoplasm Incidence in Males

		Vehicle Controls	Naïve Controls
Testes, Germinal Epithelium * Degeneration	Simple Incidence	1/20 (5.0%)	1/20 (5.0%)
	Poly-K Incidence	1/20.0 (5.0%)	1/20.0 (5.0%)
	Terminal Incidence	1/20 (5.0%)	1/20 (5.0%)
	Time-to-First	89 (T)	94 (T)
	Poly-K P-Value	0.760	0.760
	Severity Profile	0 0 0 1	1 0 0 0
	JT/SW P-Value	0.486N	0.486N
Kidney * Cyst	Simple Incidence	9/20 (45.0%)	7/20 (35.0%)
	Poly-K Incidence	9/20.0 (45.0%)	7/20.0 (35.0%)
	Terminal Incidence	9/20 (45.0%)	7/20 (35.0%)
	Time-to-First	86 (T)	86 (T)
	Poly-K P-Value	0.376N	0.376N
	Severity Profile	6 3 0 0	2 5 0 0
	JT/SW P-Value	0.403N	0.403N
Kidney, Cortex * Cyst	Simple Incidence	1/20 (5.0%)	3/20 (15.0%)
	Poly-K Incidence	1/20.0 (5.0%)	3/20.0 (15.0%)
	Terminal Incidence	1/20 (5.0%)	3/20 (15.0%)
	Time-to-First	91 (T)	86 (T)
	Poly-K P-Value	0.301	0.301
	Severity Profile	1 0 0 0	1 2 0 0
	JT/SW P-Value	0.138	0.138
Kidney, Renal Tubule * Cyst	Simple Incidence	8/20 (40.0%)	5/20 (25.0%)
	Poly-K Incidence	8/20.0 (40.0%)	5/20.0 (25.0%)
	Terminal Incidence	8/20 (40.0%)	5/20 (25.0%)
	Time-to-First	86 (T)	86 (T)
	Poly-K P-Value	0.252N	0.252N
	Severity Profile	5 3 0 0	1 4 0 0
	JT/SW P-Value	0.241N	0.241N
Kidney * Hydronephrosis	Simple Incidence	0/20 (0.0%)	3/20 (15.0%)
	Poly-K Incidence	0/20.0 (0.0%)	3/20.0 (15.0%)
	Terminal Incidence	0/20 (0.0%)	3/20 (15.0%)
	Time-to-First	----	85 (T)
	Poly-K P-Value	0.111	0.111
	Severity Profile	---	1 0 2 0
	JT/SW P-Value	0.038 *	0.038 *
Kidney * Nephropathy	Simple Incidence	14/20 (70.0%)	16/20 (80.0%)
	Poly-K Incidence	14/20.0 (70.0%)	16/20.0 (80.0%)
	Terminal Incidence	14/20 (70.0%)	16/20 (80.0%)
	Time-to-First	85 (T)	85 (T)
	Poly-K P-Value	0.360	0.360
	Severity Profile	14 0 0 0	15 1 0 0
	JT/SW P-Value	0.174	0.174
	RTE P-Value	0.190	0.190

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Heart * Cardiomyopathy	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	1/18 (5.6%)	1/21 (4.8%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	1/18.0 (5.6%)	1/21.0 (4.8%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	1/18 (5.6%)	1/21 (4.8%)
	Time-to-First	----	----	86 (T)	87 (T)
	Poly-K P-Value	0.492	---	0.479	0.510
	Severity Profile	---	---	1 0 0 0	1 0 0 0
	JT/SW P-Value	0.452	0.500	0.107	0.185
	RTE P-Value	0.477	0.500	0.147	0.139
Liver * Fatty Change	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	1/21 (4.8%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	1/21.0 (4.8%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	1/21 (4.8%)
	Time-to-First	----	----	----	95 (T)
	Poly-K P-Value	0.153	---	---	0.510
	Severity Profile	---	---	---	0 1 0 0
	JT/SW P-Value	0.134	0.500	0.583	0.105
	RTE P-Value	0.127	0.500	0.500	0.113
Liver * Fibrosis	Simple Incidence	0/20 (0.0%)	1/23 (4.3%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/23.0 (4.3%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	1/23 (4.3%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	----	93 (T)	----	----
	Poly-K P-Value	0.433	0.528	---	---
	Severity Profile	---	1 0 0 0	---	---
	JT/SW P-Value	0.369	0.176	0.333	0.407
	RTE P-Value	0.335	0.159	0.500	0.500
Liver * Hepatodiaphragmatic Nodule	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)	1/21 (4.8%)
	Poly-K Incidence	0/20.0 (0.0%)	2/23.0 (8.7%)	0/18.0 (0.0%)	1/21.0 (4.8%)
	Terminal Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)	1/21 (4.8%)
	Time-to-First	----	94 (T)	----	92 (T)
	Poly-K P-Value	0.435N	0.267	---	0.510
	Severity Profile	---	---	---	---
Liver * Infiltration Cellular	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	2/21 (9.5%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	2/21.0 (9.5%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	2/21 (9.5%)
	Time-to-First	----	----	----	88 (T)
	Poly-K P-Value	0.446N	---	---	0.245
	Severity Profile	---	---	---	2 0 0 0
	JT/SW P-Value	0.381N	0.500N	0.583N	0.858N
	RTE P-Value	0.380N	0.500	0.500	0.007 **
Liver * Granuloma	Simple Incidence	2/20 (10.0%)	2/23 (8.7%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	2/23.0 (8.7%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	2/23 (8.7%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	90 (T)	88 (T)	----	----
	Poly-K P-Value	0.488N	0.645N	0.258N	0.223N
	Severity Profile	2 0 0 0	2 0 0 0	---	---
	JT/SW P-Value	0.454N	0.442N	0.129N	0.087N
	RTE P-Value	0.476N	0.430N	0.117N	0.143N

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		BPA 80	BPA 260	BPA 840	BPA 2700
Heart * Cardiomyopathy	Simple Incidence	2/20 (10.0%)	1/21 (4.8%)	0/20 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	1/20.6 (4.9%)	0/20.0 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	1/20 (5.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	87 (T)	87 (T)	----	----
	Poly-K P-Value	0.234	0.506	---	---
	Severity Profile	2 0 0 0	1 0 0 0	---	---
	JT/SW P-Value	0.066	0.159	0.268	0.310
	RTE P-Value	0.052	0.149	0.500	0.500
Liver * Fatty Change	Simple Incidence	2/20 (10.0%)	0/21 (0.0%)	2/20 (10.0%)	0/20 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	0/20.6 (0.0%)	2/20.0 (10.0%)	0/20.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	0/20 (0.0%)	2/20 (10.0%)	0/20 (0.0%)
	Time-to-First	87 (T)	----	85 (T)	----
	Poly-K P-Value	0.234	---	0.234	---
	Severity Profile	0 2 0 0	---	0 2 0 0	---
	JT/SW P-Value	0.039 * ¹	0.211	0.055	0.250
	RTE P-Value	0.024 *	0.500	0.022 *	0.500
Liver * Fibrosis	Simple Incidence	0/20 (0.0%)	0/21 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.6 (0.0%)	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	----	----	86 (T)
	Poly-K P-Value	---	---	---	0.500
	Severity Profile	---	---	---	0 1 0 0
	JT/SW P-Value	0.457	0.488	0.513	0.100
	RTE P-Value	0.500	0.500	0.500	0.099
Liver * Hepatodiaphragmatic Nodule	Simple Incidence	1/20 (5.0%)	0/21 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/20.6 (0.0%)	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	86 (T)	----	----	86 (T)
	Poly-K P-Value	0.500	---	---	0.500
Liver * Infiltration Cellular	Simple Incidence	0/20 (0.0%)	0/21 (0.0%)	0/20 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.6 (0.0%)	0/20.0 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	----	----	----	----
	Poly-K P-Value	---	---	---	---
	Severity Profile	---	---	---	---
	JT/SW P-Value	0.636N	0.648N	0.656N	0.662N
	RTE P-Value	0.500	0.500	0.500	0.500
Liver * Granuloma	Simple Incidence	2/20 (10.0%)	1/21 (4.8%)	2/20 (10.0%)	1/20 (5.0%)
	Poly-K Incidence	2/20.0 (10.0%)	1/20.6 (4.9%)	2/20.0 (10.0%)	1/20.0 (5.0%)
	Terminal Incidence	2/20 (10.0%)	1/20 (5.0%)	2/20 (10.0%)	1/20 (5.0%)
	Time-to-First	86 (T)	95 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.696	0.490N	0.696	0.500N
	Severity Profile	2 0 0 0	1 0 0 0	2 0 0 0	1 0 0 0
	JT/SW P-Value	0.249N	0.264N	0.355N	0.355N
	RTE P-Value	0.500	0.245N	0.500	0.258N

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Pancreas, Acinar Cell * Atrophy	Simple Incidence	4/20 (20.0%)	6/23 (26.1%)	4/18 (22.2%)	4/21 (19.0%)
	Poly-K Incidence	4/20.0 (20.0%)	6/23.0 (26.1%)	4/18.0 (22.2%)	4/21.0 (19.0%)
	Terminal Incidence	4/20 (20.0%)	6/23 (26.1%)	4/18 (22.2%)	4/21 (19.0%)
	Time-to-First	85 (T)	86 (T)	85 (T)	87 (T)
	Poly-K P-Value	0.011N*	0.457	0.589	0.622N
	Severity Profile	2 2 0 0	3 2 1 0	4 0 0 0	3 1 0 0
	JT/SW P-Value	0.008N**	0.689N	0.581N	0.551N
	RTE P-Value	0.010N*	0.281	0.476	0.442N
Pancreas * Inflammation	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	----	----	----	----
	Poly-K P-Value	0.019 *	---	---	---
	Severity Profile	---	---	---	---
	JT/SW P-Value	0.015 *	0.500	0.583	0.618
	RTE P-Value	0.007 **	0.500	0.500	0.500
Pituitary Gland * Cyst	Simple Incidence	1/20 (5.0%)	0/23 (0.0%)	1/18 (5.6%)	2/21 (9.5%)
	Poly-K Incidence	1/20.0 (5.0%)	0/23.0 (0.0%)	1/18.0 (5.6%)	2/21.0 (9.5%)
	Terminal Incidence	1/20 (5.0%)	0/23 (0.0%)	1/18 (5.6%)	2/21 (9.5%)
	Time-to-First	88 (T)	----	87 (T)	87 (T)
	Poly-K P-Value	0.518	0.472N	0.737	0.517
	Severity Profile				
	JT/SW P-Value				
Thyroid Gland * Ultimobranchial Cyst	Simple Incidence	6/20 (30.0%)	12/23 (52.2%)	5/18 (27.8%)	8/21 (38.1%)
	Poly-K Incidence	6/20.0 (30.0%)	12/23.0 (52.2%)	5/18.0 (27.8%)	8/21.0 (38.1%)
	Terminal Incidence	6/20 (30.0%)	12/23 (52.2%)	5/18 (27.8%)	8/21 (38.1%)
	Time-to-First	85 (T)	85 (T)	85 (T)	86 (T)
	Poly-K P-Value	0.192N	0.123	0.580N	0.416
	Severity Profile				
	JT/SW P-Value				
Thyroid Gland * Ectopic Thymus	Simple Incidence	0/20 (0.0%)	1/23 (4.3%)	0/18 (0.0%)	3/21 (14.3%)
	Poly-K Incidence	0/20.0 (0.0%)	1/23.0 (4.3%)	0/18.0 (0.0%)	3/21.0 (14.3%)
	Terminal Incidence	0/20 (0.0%)	1/23 (4.3%)	0/18 (0.0%)	3/21 (14.3%)
	Time-to-First	----	85 (T)	----	85 (T)
	Poly-K P-Value	0.278	0.528	---	0.121
	Severity Profile				
	JT/SW P-Value				
Adrenal Cortex * Accessory Adrenal Cortical Nodule	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	----	----	----	----
	Poly-K P-Value	0.139	---	---	---
	Severity Profile				
	JT/SW P-Value				
Mammary Gland, Duct * Hyperplasia	Simple Incidence	7/20 (35.0%)	11/23 (47.8%)	6/18 (33.3%)	11/21 (52.4%)
	Poly-K Incidence	7/20.0 (35.0%)	11/23.0 (47.8%)	6/18.0 (33.3%)	11/21.0 (52.4%)
	Terminal Incidence	7/20 (35.0%)	11/23 (47.8%)	6/18 (33.3%)	11/21 (52.4%)
	Time-to-First	85 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.210	0.297	0.590N	0.212
	Severity Profile	7 0 0 0	7 4 0 0	4 2 0 0	10 1 0 0
	JT/SW P-Value	0.056	0.113	0.287	0.166
	RTE P-Value	0.050 *	0.134	0.419	0.162

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		BPA 80	BPA 260	BPA 840	BPA 2700
Pancreas, Acinar Cell * Atrophy	Simple Incidence	2/20 (10.0%)	3/21 (14.3%)	1/20 (5.0%)	1/20 (5.0%)
	Poly-K Incidence	2/20.0 (10.0%)	3/20.6 (14.6%)	1/20.0 (5.0%)	1/20.0 (5.0%)
	Terminal Incidence	2/20 (10.0%)	3/20 (15.0%)	1/20 (5.0%)	1/20 (5.0%)
	Time-to-First	87 (T)	88 (T)	87 (T)	85 (T)
	Poly-K P-Value	0.331N	0.484N	0.169N	0.169N
	Severity Profile	1 1 0 0	3 0 0 0	0 0 1 0	1 0 0 0
	JT/SW P-Value	0.278N	0.324N	0.147N	0.115N
Pancreas * Inflammation	RTE P-Value	0.182N	0.273N	0.104N	0.079N
	Simple Incidence	0/20 (0.0%)	0/21 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.6 (0.0%)	0/20.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	----	----	----	86 (T)
	Poly-K P-Value	---	---	---	0.234
	Severity Profile	---	---	---	0 2 0 0
Pituitary Gland * Cyst	JT/SW P-Value	0.636	0.648	0.656	0.002 **
	RTE P-Value	0.500	0.500	0.500	0.007 **
	Simple Incidence	2/20 (10.0%)	0/21 (0.0%)	2/20 (10.0%)	0/20 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	0/20.6 (0.0%)	2/20.0 (10.0%)	0/20.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	0/20 (0.0%)	2/20 (10.0%)	0/20 (0.0%)
	Time-to-First	86 (T)	----	85 (T)	----
	Poly-K P-Value	0.500	0.494N	0.500	0.500N
Thyroid Gland * Ultimobranchial Cyst	Simple Incidence	6/20 (30.0%)	4/21 (19.0%)	6/20 (30.0%)	7/20 (35.0%)
	Poly-K Incidence	6/20.0 (30.0%)	4/20.6 (19.4%)	6/20.0 (30.0%)	7/20.0 (35.0%)
	Terminal Incidence	6/20 (30.0%)	4/20 (20.0%)	6/20 (30.0%)	7/20 (35.0%)
	Time-to-First	86 (T)	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.632	0.341N	0.632	0.500
	Simple Incidence	0/20 (0.0%)	3/21 (14.3%)	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	3/21.0 (14.3%)	0/20.0 (0.0%)	1/20.0 (5.0%)
Thyroid Gland * Ectopic Thymus	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	79	----	95 (T)
	Poly-K P-Value	---	0.121	---	0.500
	Simple Incidence	0/20 (0.0%)	1/21 (4.8%)	1/20 (5.0%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.6 (4.9%)	1/20.0 (5.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	1/20 (5.0%)	0/20 (0.0%)
	Time-to-First	----	86 (T)	86 (T)	----
Adrenal Cortex * Accessory Adrenal Cortical Nodule	Poly-K P-Value	---	0.506	0.500	---
	Simple Incidence	8/20 (40.0%)	8/21 (38.1%)	9/20 (45.0%)	11/20 (55.0%)
	Poly-K Incidence	8/20.0 (40.0%)	8/20.6 (38.9%)	9/20.0 (45.0%)	11/20.0 (55.0%)
	Terminal Incidence	8/20 (40.0%)	8/20 (40.0%)	9/20 (45.0%)	11/20 (55.0%)
	Time-to-First	85 (T)	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.500	0.527	0.376	0.171
	Severity Profile	1 7 0 0	3 5 0 0	5 4 0 0	4 7 0 0
Mammary Gland, Duct * Hyperplasia	JT/SW P-Value	0.157	0.215	0.205	0.034 *
	RTE P-Value	0.114	0.215	0.153	0.030 *

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Mammary Gland, Alveolus * Hyperplasia	Simple Incidence	6/20 (30.0%)	5/23 (21.7%)	3/18 (16.7%)	6/21 (28.6%)
	Poly-K Incidence	6/20.0 (30.0%)	5/23.0 (21.7%)	3/18.0 (16.7%)	6/21.0 (28.6%)
	Terminal Incidence	6/20 (30.0%)	5/23 (21.7%)	3/18 (16.7%)	6/21 (28.6%)
	Time-to-First	85 (T)	88 (T)	88 (T)	86 (T)
	Poly-K P-Value	0.178	0.396N	0.283N	0.594N
	Severity Profile	5 1 0 0	2 3 0 0	3 0 0 0	2 2 2 0
	JT/SW P-Value	0.134	0.655	0.829	0.528
Mammary Gland, Alveolus * Hyperplasia (adjusted for pseudo-pregnancy)	Simple Incidence	5/17 (29.4%)	3/21 (14.3%)	3/18 (16.7%)	5/20 (25.0%)
	Poly-K Incidence	5/17.0 (29.4%)	3/21.0 (14.3%)	3/18.0 (16.7%)	5/20.0 (25.0%)
	Terminal Incidence	5/17 (29.4%)	3/21 (14.3%)	3/18 (16.7%)	5/20 (25.0%)
	Time-to-First	85 (T)	88 (T)	88 (T)	86 (T)
	Poly-K P-Value	0.157	0.233N	0.313N	0.527N
	Severity Profile	4 1 0 0	2 1 0 0	3 0 0 0	1 2 2 0
	JT/SW P-Value	0.132	0.859	0.904	0.639
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	11/20 (55.0%)	12/23 (52.2%)	6/18 (33.3%)	11/21 (52.4%)
	Poly-K Incidence	11/20.0 (55.0%)	12/23.0 (52.2%)	6/18.0 (33.3%)	11/21.0 (52.4%)
	Terminal Incidence	11/20 (55.0%)	12/23 (52.2%)	6/18 (33.3%)	11/21 (52.4%)
	Time-to-First	85 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.459	0.547N	0.156N	0.556N
	Severity Profile	10 1 0 0	7 5 0 0	4 2 0 0	6 3 2 0
	JT/SW P-Value	0.136	0.345	0.678	0.399
Mammary Gland, Duct or Alveolus * Hyperplasia (adjusted for pseudo-pregnancy)	Simple Incidence	11/19 (57.9%)	12/23 (52.2%)	6/18 (33.3%)	11/21 (52.4%)
	Poly-K Incidence	11/19.0 (57.9%)	12/23.0 (52.2%)	6/18.0 (33.3%)	11/21.0 (52.4%)
	Terminal Incidence	11/19 (57.9%)	12/23 (52.2%)	6/18 (33.3%)	11/21 (52.4%)
	Time-to-First	85 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.402	0.477N	0.120N	0.488N
	Severity Profile	10 1 0 0	7 5 0 0	4 2 0 0	6 3 2 0
	JT/SW P-Value	0.104	0.402	0.732	0.467
Lymph Node, Mandibular * Hemorrhage	Simple Incidence	0/20 (0.0%)	1/23 (4.3%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/23.0 (4.3%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	1/23 (4.3%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	----	87 (T)	----	----
	Poly-K P-Value	0.444N	0.528	---	---
	Severity Profile	---	0 1 0 0	---	---
	JT/SW P-Value	0.389N	0.824N	0.583N	0.618N
Lymph Node, Mandibular * Hyperplasia	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	2/21 (9.5%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	2/21.0 (9.5%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	2/21 (9.5%)
	Time-to-First	----	----	----	88 (T)
	Poly-K P-Value	0.200	---	---	0.245
	Severity Profile	---	---	---	0 1 0 1
	JT/SW P-Value	0.184	0.500	0.583	0.030 * ¹
Lymph Node, Mandibular * Hyperplasia	RTE P-Value	0.190	0.500	0.500	0.060

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		BPA 80	BPA 260	BPA 840	BPA 2700
Mammary Gland, Alveolus * Hyperplasia	Simple Incidence	7/20 (35.0%)	5/21 (23.8%)	4/20 (20.0%)	9/20 (45.0%)
	Poly-K Incidence	7/20.0 (35.0%)	5/20.6 (24.3%)	4/20.0 (20.0%)	9/20.0 (45.0%)
	Terminal Incidence	7/20 (35.0%)	5/20 (25.0%)	4/20 (20.0%)	9/20 (45.0%)
	Time-to-First	85 (T)	89 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.500	0.479N	0.360N	0.260
	Severity Profile	5 2 0 0	4 1 0 0	1 1 2 0	4 5 0 0
	JT/SW P-Value	0.451	0.618	0.681	0.138
	RTE P-Value	0.347	0.349N	0.361N	0.102
Mammary Gland, Alveolus * Hyperplasia (adjusted for pseudo- pregnancy)	Simple Incidence	6/19 (31.6%)	5/20 (25.0%)	3/17 (17.6%)	7/17 (41.2%)
	Poly-K Incidence	6/19.0 (31.6%)	5/19.6 (25.5%)	3/17.0 (17.6%)	7/17.0 (41.2%)
	Terminal Incidence	6/19 (31.6%)	5/19 (26.3%)	3/17 (17.6%)	7/17 (41.2%)
	Time-to-First	85 (T)	89 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.585	0.543N	0.346N	0.363
	Severity Profile	5 1 0 0	4 1 0 0	1 0 2 0	4 3 0 0
	JT/SW P-Value	0.577	0.678	0.737	0.259
	RTE P-Value	0.450	0.386N	0.289N	0.190
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	9/20 (45.0%)	10/21 (47.6%)	10/20 (50.0%)	11/20 (55.0%)
	Poly-K Incidence	9/20.0 (45.0%)	10/20.6 (48.6%)	10/20.0 (50.0%)	11/20.0 (55.0%)
	Terminal Incidence	9/20 (45.0%)	10/20 (50.0%)	10/20 (50.0%)	11/20 (55.0%)
	Time-to-First	85 (T)	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.378N	0.463N	0.500N	0.622
	Severity Profile	2 7 0 0	5 5 0 0	4 4 2 0	3 8 0 0
	JT/SW P-Value	0.440	0.486	0.388	0.229
	RTE P-Value	0.354	0.426	0.274	0.171
Mammary Gland, Duct or Alveolus * Hyperplasia (adjusted for pseudo- pregnancy)	Simple Incidence	9/20 (45.0%)	10/20 (50.0%)	10/19 (52.6%)	11/19 (57.9%)
	Poly-K Incidence	9/20.0 (45.0%)	10/19.6 (51.1%)	10/19.0 (52.6%)	11/19.0 (57.9%)
	Terminal Incidence	9/20 (45.0%)	10/19 (52.6%)	10/19 (52.6%)	11/19 (57.9%)
	Time-to-First	85 (T)	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.317N	0.460N	0.500N	0.625
	Severity Profile	2 7 0 0	5 5 0 0	4 4 2 0	3 8 0 0
	JT/SW P-Value	0.506	0.528	0.374	0.213
	RTE P-Value	0.398	0.420	0.262	0.158
Lymph Node, Mandibular * Hemorrhage	Simple Incidence	0/20 (0.0%)	1/21 (4.8%)	0/20 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.6 (4.9%)	0/20.0 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	----	87 (T)	----	----
	Poly-K P-Value	---	0.506	---	---
	Severity Profile	---	0 0 0 1	---	---
	JT/SW P-Value	0.636N	0.777N	0.656N	0.662N
	RTE P-Value	0.500	0.104	0.500	0.500
Lymph Node, Mandibular * Hyperplasia	Simple Incidence	2/20 (10.0%)	1/21 (4.8%)	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	2/20.0 (10.0%)	1/20.6 (4.9%)	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	2/20 (10.0%)	1/20 (5.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	85 (T)	87 (T)	----	87 (T)
	Poly-K P-Value	0.234	0.506	---	0.500
	Severity Profile	0 0 0 2	0 0 1 0	---	0 1 0 0
	JT/SW P-Value	0.064	0.128	0.202	0.224
	RTE P-Value	0.029 *	0.212	0.500	0.207

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Lung * Inflammation	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	1/18 (5.6%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	1/18.0 (5.6%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	1/18 (5.6%)	0/21 (0.0%)
	Time-to-First	----	----	86 (T)	----
	Poly-K P-Value	0.338N	---	0.479	---
	Severity Profile	---	---	0 1 0 0	---
	JT/SW P-Value	0.264N	0.500N	0.805N	0.618N
	RTE P-Value	0.229N	0.500	0.055	0.500
Ovary * Cyst	Simple Incidence	4/20 (20.0%)	7/23 (30.4%)	2/18 (11.1%)	9/21 (42.9%)
	Poly-K Incidence	4/20.0 (20.0%)	7/23.0 (30.4%)	2/18.0 (11.1%)	9/21.0 (42.9%)
	Terminal Incidence	4/20 (20.0%)	7/23 (30.4%)	2/18 (11.1%)	9/21 (42.9%)
	Time-to-First	85 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.253	0.336	0.383N	0.107
Ovary, Parenchyma * Cyst	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	----	----	----	----
	Poly-K P-Value	0.189	---	---	---
Ovary, Corpus Luteum * Cyst	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)	2/21 (9.5%)
	Poly-K Incidence	0/20.0 (0.0%)	2/23.0 (8.7%)	0/18.0 (0.0%)	2/21.0 (9.5%)
	Terminal Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)	2/21 (9.5%)
	Time-to-First	----	88 (T)	----	86 (T)
	Poly-K P-Value	0.171N	0.267	---	0.245
Ovary, Follicle * Cyst	Simple Incidence	4/20 (20.0%)	3/23 (13.0%)	1/18 (5.6%)	7/21 (33.3%)
	Poly-K Incidence	4/20.0 (20.0%)	3/23.0 (13.0%)	1/18.0 (5.6%)	7/21.0 (33.3%)
	Terminal Incidence	4/20 (20.0%)	3/23 (13.0%)	1/18 (5.6%)	7/21 (33.3%)
	Time-to-First	85 (T)	90 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.078	0.421N	0.203N	0.273
	Severity Profile	0 4 0 0	1 2 0 0	1 0 0 0	3 4 0 0
	JT/SW P-Value	0.097	0.753	0.909	0.220
	RTE P-Value	0.090	0.251N	0.099N	0.190
Ovary, Rete Ovarii * Cyst	Simple Incidence	1/20 (5.0%)	2/23 (8.7%)	1/18 (5.6%)	1/21 (4.8%)
	Poly-K Incidence	1/20.0 (5.0%)	2/23.0 (8.7%)	1/18.0 (5.6%)	1/21.0 (4.8%)
	Terminal Incidence	1/20 (5.0%)	2/23 (8.7%)	1/18 (5.6%)	1/21 (4.8%)
	Time-to-First	95 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.216N	0.549	0.737	0.749N
Ovary, Corpus Luteum * Hypertrophy	Simple Incidence	4/20 (20.0%)	2/23 (8.7%)	2/18 (11.1%)	2/21 (9.5%)
	Poly-K Incidence	4/20.0 (20.0%)	2/23.0 (8.7%)	2/18.0 (11.1%)	2/21.0 (9.5%)
	Terminal Incidence	4/20 (20.0%)	2/23 (8.7%)	2/18 (11.1%)	2/21 (9.5%)
	Time-to-First	85 (T)	94 (T)	87 (T)	89 (T)
	Poly-K P-Value	0.451	0.268N	0.383N	0.309N

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		BPA 80	BPA 260	BPA 840	BPA 2700
Lung * Inflammation	Simple Incidence	0/20 (0.0%)	0/21 (0.0%)	0/20 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.6 (0.0%)	0/20.0 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	----	----	----	----
	Poly-K P-Value	---	---	---	---
	Severity Profile	---	---	---	---
	JT/SW P-Value	0.636N	0.648N	0.656N	0.662N
	RTE P-Value	0.500	0.500	0.500	0.500
Ovary * Cyst	Simple Incidence	5/20 (25.0%)	3/20 (15.0%)	6/20 (30.0%)	7/20 (35.0%)
	Poly-K Incidence	5/20.0 (25.0%)	3/19.6 (15.3%)	6/20.0 (30.0%)	7/20.0 (35.0%)
	Terminal Incidence	5/20 (25.0%)	3/19 (15.8%)	6/20 (30.0%)	7/20 (35.0%)
	Time-to-First	85 (T)	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.500	0.512N	0.360	0.242
Ovary, Parenchyma * Cyst	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/19.6 (0.0%)	1/20.0 (5.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/19 (0.0%)	1/20 (5.0%)	0/20 (0.0%)
	Time-to-First	----	----	87 (T)	----
	Poly-K P-Value	---	---	0.500	---
Ovary, Corpus Luteum * Cyst	Simple Incidence	1/20 (5.0%)	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/19.6 (0.0%)	0/20.0 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/19 (0.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	87 (T)	----	----	----
	Poly-K P-Value	0.500	---	---	---
Ovary, Follicle * Cyst	Simple Incidence	5/20 (25.0%)	2/20 (10.0%)	5/20 (25.0%)	7/20 (35.0%)
	Poly-K Incidence	5/20.0 (25.0%)	2/19.6 (10.2%)	5/20.0 (25.0%)	7/20.0 (35.0%)
	Terminal Incidence	5/20 (25.0%)	2/19 (10.5%)	5/20 (25.0%)	7/20 (35.0%)
	Time-to-First	85 (T)	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.500	0.342N	0.500	0.242
	Severity Profile	1 4 0 0	0 2 0 0	3 2 0 0	3 4 0 0
	JT/SW P-Value	0.353	0.577	0.566	0.220
	RTE P-Value	0.369	0.188N	0.432	0.156
Ovary, Rete Ovarii * Cyst	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/19.6 (5.1%)	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/19 (5.3%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	87 (T)	----	86 (T)
	Poly-K P-Value	0.500N	0.756	0.500N	0.760
Ovary, Corpus Luteum * Hypertrophy	Simple Incidence	1/20 (5.0%)	2/20 (10.0%)	4/20 (20.0%)	3/20 (15.0%)
	Poly-K Incidence	1/20.0 (5.0%)	2/19.6 (10.2%)	4/20.0 (20.0%)	3/20.0 (15.0%)
	Terminal Incidence	1/20 (5.0%)	2/19 (10.5%)	4/20 (20.0%)	3/20 (15.0%)
	Time-to-First	93 (T)	95 (T)	85 (T)	95 (T)
	Poly-K P-Value	0.169N	0.342N	0.650	0.500N

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Ovary, Corpus Luteum * Depletion	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	2/18 (11.1%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/23.0 (8.7%)	2/18.0 (11.1%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	2/23 (8.7%)	2/18 (11.1%)	0/21 (0.0%)
	Time-to-First	----	94 (T)	86 (T)	----
	Poly-K P-Value	0.205	0.267	0.210	---
	Severity Profile	---	0 2 0 0	2 0 0 0	---
	JT/SW P-Value	0.184	0.091	0.110	0.218
	RTE P-Value	0.179	0.090	0.133	0.500
Ovary, Antral Follicles * Depletion	Simple Incidence	3/20 (15.0%)	1/23 (4.3%)	1/18 (5.6%)	0/21 (0.0%)
	Poly-K Incidence	3/20.0 (15.0%)	1/23.0 (4.3%)	1/18.0 (5.6%)	0/21.0 (0.0%)
	Terminal Incidence	3/20 (15.0%)	1/23 (4.3%)	1/18 (5.6%)	0/21 (0.0%)
	Time-to-First	85 (T)	95 (T)	88 (T)	----
	Poly-K P-Value	0.331N	0.252N	0.340N	0.103N
Uterus, Endometrium * Vacuolization Cytoplasmic	Simple Incidence	3/20 (15.0%)	3/23 (13.0%)	0/18 (0.0%)	1/21 (4.8%)
	Poly-K Incidence	3/20.0 (15.0%)	3/23.0 (13.0%)	0/18.0 (0.0%)	1/21.0 (4.8%)
	Terminal Incidence	3/20 (15.0%)	3/23 (13.0%)	0/18 (0.0%)	1/21 (4.8%)
	Time-to-First	85 (T)	90 (T)	----	89 (T)
	Poly-K P-Value	0.183	0.599N	0.130N	0.284N
Uterus, Endometrium * Hyperplasia	Simple Incidence	1/20 (5.0%)	0/23 (0.0%)	4/18 (22.2%)	2/21 (9.5%)
	Poly-K Incidence	1/20.0 (5.0%)	0/23.0 (0.0%)	4/18.0 (22.2%)	2/21.0 (9.5%)
	Terminal Incidence	1/20 (5.0%)	0/23 (0.0%)	4/18 (22.2%)	2/21 (9.5%)
	Time-to-First	88 (T)	----	86 (T)	85 (T)
	Poly-K P-Value	0.431N	0.472N	0.137	0.517
	Severity Profile	0 1 0 0	---	4 0 0 0	2 0 0 0
	JT/SW P-Value	0.392N	0.142N	0.769N	0.797N
	RTE P-Value	0.339N	0.233N	0.016 *	0.285
Uterus, Endometrium * Metaplasia	Simple Incidence	1/20 (5.0%)	3/23 (13.0%)	2/18 (11.1%)	3/21 (14.3%)
	Poly-K Incidence	1/20.0 (5.0%)	3/23.0 (13.0%)	2/18.0 (11.1%)	3/21.0 (14.3%)
	Terminal Incidence	1/20 (5.0%)	3/23 (13.0%)	2/18 (11.1%)	3/21 (14.3%)
	Time-to-First	88 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.453N	0.354	0.463	0.319
	Severity Profile	1 0 0 0	3 0 0 0	2 0 0 0	3 0 0 0
	JT/SW P-Value	0.425N	0.815N	0.817N	0.889N
	RTE P-Value	0.438N	0.195	0.266	0.174
Vagina, Mucocyte * Hyperplasia	Simple Incidence	3/20 (15.0%)	2/23 (8.7%)	1/18 (5.6%)	1/21 (4.8%)
	Poly-K Incidence	3/20.0 (15.0%)	2/23.0 (8.7%)	1/18.0 (5.6%)	1/21.0 (4.8%)
	Terminal Incidence	3/20 (15.0%)	2/23 (8.7%)	1/18 (5.6%)	1/21 (4.8%)
	Time-to-First	85 (T)	94 (T)	87 (T)	89 (T)
	Poly-K P-Value	0.390	0.435N	0.340N	0.284N
Kidney, Renal Tubule * Mineralization	Simple Incidence	14/20 (70.0%)	21/23 (91.3%)	16/18 (88.9%)	19/21 (90.5%)
	Poly-K Incidence	14/20.0 (70.0%)	21/23.0 (91.3%)	16/18.0 (88.9%)	19/21.0 (90.5%)
	Terminal Incidence	14/20 (70.0%)	21/23 (91.3%)	16/18 (88.9%)	19/21 (90.5%)
	Time-to-First	85 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.107	0.078	0.152	0.102
	Severity Profile	11 3 0 0	19 0 1 1	13 2 1 0	17 2 0 0
	JT/SW P-Value	0.296	0.149	0.135	0.166
	RTE P-Value	0.296	0.133	0.097	0.152

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		BPA 80	BPA 260	BPA 840	BPA 2700
Ovary, Corpus Luteum * Depletion	Simple Incidence	1/20 (5.0%)	1/20 (5.0%)	2/20 (10.0%)	2/20 (10.0%)
	Poly-K Incidence	1/20.0 (5.0%)	1/19.6 (5.1%)	2/20.0 (10.0%)	2/20.0 (10.0%)
	Terminal Incidence	1/20 (5.0%)	1/19 (5.3%)	2/20 (10.0%)	2/20 (10.0%)
	Time-to-First	87 (T)	95 (T)	88 (T)	95 (T)
	Poly-K P-Value	0.500	0.496	0.234	0.234
	Severity Profile	0 1 0 0	1 0 0 0	0 2 0 0	1 1 0 0
	JT/SW P-Value	0.248	0.265	0.108	0.126
	RTE P-Value	0.253	0.266	0.082	0.126
Ovary, Antral Follicles * Depletion	Simple Incidence	2/20 (10.0%)	0/20 (0.0%)	1/20 (5.0%)	2/20 (10.0%)
	Poly-K Incidence	2/20.0 (10.0%)	0/19.6 (0.0%)	1/20.0 (5.0%)	2/20.0 (10.0%)
	Terminal Incidence	2/20 (10.0%)	0/19 (0.0%)	1/20 (5.0%)	2/20 (10.0%)
	Time-to-First	85 (T)	----	88 (T)	95 (T)
	Poly-K P-Value	0.500N	0.115N	0.301N	0.500N
Uterus, Endometrium * Vacuolization Cytoplasmic	Simple Incidence	2/20 (10.0%)	2/21 (9.5%)	5/20 (25.0%)	3/20 (15.0%)
	Poly-K Incidence	2/20.0 (10.0%)	2/20.6 (9.7%)	5/20.0 (25.0%)	3/20.0 (15.0%)
	Terminal Incidence	2/20 (10.0%)	2/20 (10.0%)	5/20 (25.0%)	3/20 (15.0%)
	Time-to-First	85 (T)	95 (T)	85 (T)	95 (T)
	Poly-K P-Value	0.500N	0.487N	0.349	0.667
Uterus, Endometrium * Hyperplasia	Simple Incidence	0/20 (0.0%)	0/21 (0.0%)	2/20 (10.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.6 (0.0%)	2/20.0 (10.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)	1/20 (5.0%)
	Time-to-First	----	----	89 (T)	85 (T)
	Poly-K P-Value	0.500N	0.494N	0.500	0.760
	Severity Profile	---	---	2 0 0 0	1 0 0 0
	JT/SW P-Value	0.338N	0.319N	0.535N	0.565N
	RTE P-Value	0.158N	0.190N	0.267	0.484N
Uterus, Endometrium * Metaplasia	Simple Incidence	3/20 (15.0%)	1/21 (4.8%)	0/20 (0.0%)	3/20 (15.0%)
	Poly-K Incidence	3/20.0 (15.0%)	1/20.6 (4.9%)	0/20.0 (0.0%)	3/20.0 (15.0%)
	Terminal Incidence	3/20 (15.0%)	1/20 (5.0%)	0/20 (0.0%)	3/20 (15.0%)
	Time-to-First	86 (T)	87 (T)	----	86 (T)
	Poly-K P-Value	0.301	0.754N	0.500N	0.301
	Severity Profile	3 0 0 0	1 0 0 0	---	3 0 0 0
	JT/SW P-Value	0.908N	0.637N	0.400N	0.733N
	RTE P-Value	0.172	0.490N	0.300N	0.173
Vagina, Mucocyte * Hyperplasia	Simple Incidence	1/20 (5.0%)	1/21 (4.8%)	3/20 (15.0%)	3/20 (15.0%)
	Poly-K Incidence	1/20.0 (5.0%)	1/20.6 (4.9%)	3/20.0 (15.0%)	3/20.0 (15.0%)
	Terminal Incidence	1/20 (5.0%)	1/20 (5.0%)	3/20 (15.0%)	3/20 (15.0%)
	Time-to-First	93 (T)	95 (T)	85 (T)	95 (T)
	Poly-K P-Value	0.301N	0.291N	0.667	0.667
Kidney, Renal Tubule * Mineralization	Simple Incidence	20/20 (100.0%)	19/21 (90.5%)	17/20 (85.0%)	18/20 (90.0%)
	Poly-K Incidence	20/20.0 (100.0%)	19/21.0 (90.5%)	17/20.0 (85.0%)	18/20.0 (90.0%)
	Terminal Incidence	20/20 (100.0%)	18/20 (90.0%)	17/20 (85.0%)	18/20 (90.0%)
	Time-to-First	85 (T)	79	85 (T)	85 (T)
	Poly-K P-Value	0.009 **	0.102	0.227	0.116
	Severity Profile	16 3 1 0	17 2 0 0	15 2 0 0	16 2 0 0
	JT/SW P-Value	0.017 * ¹	0.070	0.135	0.153
	RTE P-Value	0.015 *	0.153	0.260	0.162

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Kidney, Renal Tubule * Cyst	Simple Incidence	1/20 (5.0%)	5/23 (21.7%)	5/18 (27.8%)	8/21 (38.1%)
	Poly-K Incidence	1/20.0 (5.0%)	5/23.0 (21.7%)	5/18.0 (27.8%)	8/21.0 (38.1%)
	Terminal Incidence	1/20 (5.0%)	5/23 (21.7%)	5/18 (27.8%)	8/21 (38.1%)
	Time-to-First	88 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.074	0.126	0.065	0.010 *
	Severity Profile	1 0 0 0	2 2 0 1	4 0 1 0	5 3 0 0
	JT/SW P-Value	0.088	0.053	0.045 *	0.007 **
	RTE P-Value	0.086	0.086	0.064	0.007 **
Kidney * Nephropathy	Simple Incidence	12/20 (60.0%)	16/23 (69.6%)	15/18 (83.3%)	20/21 (95.2%)
	Poly-K Incidence	12/20.0 (60.0%)	16/23.0 (69.6%)	15/18.0 (83.3%)	20/21.0 (95.2%)
	Terminal Incidence	12/20 (60.0%)	16/23 (69.6%)	15/18 (83.3%)	20/21 (95.2%)
	Time-to-First	85 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.148	0.371	0.109	0.006 **
	Severity Profile	12 0 0 0	15 1 0 0	15 0 0 0	19 1 0 0
	JT/SW P-Value	0.064	0.209	0.077	0.003 ** 1
	RTE P-Value	0.072	0.188	0.069	0.007 **

Table 3: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Females

		BPA 80	BPA 260	BPA 840	BPA 2700
Kidney, Renal Tubule * Cyst	Simple Incidence	6/20 (30.0%)	6/21 (28.6%)	5/20 (25.0%)	6/20 (30.0%)
	Poly-K Incidence	6/20.0 (30.0%)	6/20.6 (29.2%)	5/20.0 (25.0%)	6/20.0 (30.0%)
	Terminal Incidence	6/20 (30.0%)	6/20 (30.0%)	5/20 (25.0%)	6/20 (30.0%)
	Time-to-First	85 (T)	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.043 *	0.048 *	0.089	0.043 *
	Severity Profile	4 0 2 0	5 1 0 0	3 0 2 0	5 1 0 0
	JT/SW P-Value	0.020 *	0.028 *	0.040 *	0.043 *
	RTE P-Value	0.033 *	0.052	0.064	0.042 *
Kidney * Nephropathy	Simple Incidence	17/20 (85.0%)	14/21 (66.7%)	13/20 (65.0%)	18/20 (90.0%)
	Poly-K Incidence	17/20.0 (85.0%)	14/21.0 (66.7%)	13/20.0 (65.0%)	18/20.0 (90.0%)
	Terminal Incidence	17/20 (85.0%)	13/20 (65.0%)	13/20 (65.0%)	18/20 (90.0%)
	Time-to-First	85 (T)	79	85 (T)	85 (T)
	Poly-K P-Value	0.075	0.454	0.500	0.029 *
	Severity Profile	16 1 0 0	11 3 0 0	10 2 1 0	18 0 0 0
	JT/SW P-Value	0.009 ** 1	0.034 * 1	0.068	0.032 *
	RTE P-Value	0.028 *	0.123	0.135	0.026 *

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Heart * Cardiomyopathy	Simple Incidence	7/20 (35.0%)	9/23 (39.1%)	6/18 (33.3%)	6/21 (28.6%)
	Poly-K Incidence	7/20.0 (35.0%)	9/23.0 (39.1%)	6/18.0 (33.3%)	6/21.0 (28.6%)
	Terminal Incidence	7/20 (35.0%)	9/23 (39.1%)	6/18 (33.3%)	6/21 (28.6%)
	Time-to-First	85 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.287N	0.514	0.590N	0.459N
	Severity Profile	6 1 0 0	7 2 0 0	6 0 0 0	5 1 0 0
	JT/SW P-Value	0.240N	0.634N	0.491N	0.432N
	RTE P-Value	0.252N	0.363	0.418N	0.340N
Liver * Vacuolization Cytoplasmic	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	2/18 (11.1%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/23.0 (8.7%)	2/18.0 (11.1%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	2/23 (8.7%)	2/18 (11.1%)	0/21 (0.0%)
	Time-to-First	----	85 (T)	89 (T)	----
	Poly-K P-Value	0.166N	0.267	0.210	---
	Severity Profile	---	2 0 0 0	2 0 0 0	---
	JT/SW P-Value	0.152N	0.909N	0.939N	0.618N
	RTE P-Value	0.154N	0.050	0.041 *	0.500
Liver * Hepatodiaphragmatic Nodule	Simple Incidence	1/20 (5.0%)	0/23 (0.0%)	1/18 (5.6%)	1/21 (4.8%)
	Poly-K Incidence	1/20.0 (5.0%)	0/23.0 (0.0%)	1/18.0 (5.6%)	1/21.0 (4.8%)
	Terminal Incidence	1/20 (5.0%)	0/23 (0.0%)	1/18 (5.6%)	1/21 (4.8%)
	Time-to-First	90 (T)	----	90 (T)	85 (T)
	Poly-K P-Value	0.346N	0.472N	0.737	0.749N
	Severity Profile	4 0 0 0	4 3 0 0	3 0 1 0	6 1 1 0
	JT/SW P-Value	0.338	0.169	0.321	0.107
	RTE P-Value	0.321	0.183	0.399	0.089
Pancreas, Acinus * Degeneration	Simple Incidence	4/20 (20.0%)	7/23 (30.4%)	4/18 (22.2%)	8/21 (38.1%)
	Poly-K Incidence	4/20.0 (20.0%)	7/23.0 (30.4%)	4/18.0 (22.2%)	8/21.0 (38.1%)
	Terminal Incidence	4/20 (20.0%)	7/23 (30.4%)	4/18 (22.2%)	8/21 (38.1%)
	Time-to-First	90 (T)	87 (T)	86 (T)	86 (T)
	Poly-K P-Value	0.331	0.336	0.589	0.177
	Severity Profile	4 0 0 0	4 3 0 0	3 0 1 0	6 1 1 0
	JT/SW P-Value	0.338	0.169	0.321	0.107
	RTE P-Value	0.321	0.183	0.399	0.089
Pancreas * Inflammation	Simple Incidence	2/20 (10.0%)	1/23 (4.3%)	1/18 (5.6%)	6/21 (28.6%)
	Poly-K Incidence	2/20.0 (10.0%)	1/23.0 (4.3%)	1/18.0 (5.6%)	6/21.0 (28.6%)
	Terminal Incidence	2/20 (10.0%)	1/23 (4.3%)	1/18 (5.6%)	6/21 (28.6%)
	Time-to-First	90 (T)	92 (T)	90 (T)	86 (T)
	Poly-K P-Value	0.475	0.451N	0.537N	0.134
	Severity Profile	2 0 0 0	0 1 0 0	0 1 0 0	4 1 1 0
	JT/SW P-Value	0.464	0.746	0.772	0.040 * ¹
	RTE P-Value	0.461	0.297N	0.354N	0.028 *
Pancreas * Infiltration Cellular	Simple Incidence	2/20 (10.0%)	5/23 (21.7%)	0/18 (0.0%)	2/21 (9.5%)
	Poly-K Incidence	2/20.0 (10.0%)	5/23.0 (21.7%)	0/18.0 (0.0%)	2/21.0 (9.5%)
	Terminal Incidence	2/20 (10.0%)	5/23 (21.7%)	0/18 (0.0%)	2/21 (9.5%)
	Time-to-First	90 (T)	90 (T)	----	90 (T)
	Poly-K P-Value	0.440	0.268	0.258N	0.678N
	Severity Profile	2 0 0 0	5 0 0 0	---	2 0 0 0
	JT/SW P-Value	0.425	0.152	0.492	0.559
	RTE P-Value	0.381	0.143	0.146N	0.481N

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		BPA 80	BPA 260	BPA 840	BPA 2700
Heart * Cardiomyopathy	Simple Incidence	6/20 (30.0%)	9/20 (45.0%)	6/21 (28.6%)	5/20 (25.0%)
	Poly-K Incidence	6/20.0 (30.0%)	9/20.0 (45.0%)	6/20.2 (29.8%)	5/20.0 (25.0%)
	Terminal Incidence	6/20 (30.0%)	9/20 (45.0%)	6/20 (30.0%)	5/20 (25.0%)
	Time-to-First	88 (T)	85 (T)	85 (T)	87 (T)
	Poly-K P-Value	0.500N	0.376	0.494N	0.368N
	Severity Profile	6 0 0 0	7 2 0 0	5 1 0 0	5 0 0 0
	JT/SW P-Value	0.440N	0.613N	0.463N	0.317N
	RTE P-Value	0.337N	0.231	0.340N	0.231N
Liver * Vacuolization Cytoplasmic	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	1/21 (4.8%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	1/20.2 (5.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)	0/20 (0.0%)
	Time-to-First	----	----	90 (T)	----
	Poly-K P-Value	---	---	0.501	---
	Severity Profile	---	---	0 1 0 0	---
	JT/SW P-Value	0.636N	0.648N	0.748N	0.662N
	RTE P-Value	0.500	0.500	0.091	0.500
Liver * Hepatodiaphragmatic Nodule	Simple Incidence	2/20 (10.0%)	1/20 (5.0%)	0/21 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	1/20.0 (5.0%)	0/20.2 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	1/20 (5.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	86 (T)	90 (T)	----	----
	Poly-K P-Value	0.500	0.760	0.499N	0.500N
	Severity Profile	3 1 0 1	3 2 2 0	5 0 0 0	5 1 0 0
	JT/SW P-Value	0.227	0.121	0.263	0.279
	RTE P-Value	0.301	0.095	0.404	0.237
Pancreas, Acinus * Degeneration	Simple Incidence	5/20 (25.0%)	7/20 (35.0%)	5/21 (23.8%)	6/20 (30.0%)
	Poly-K Incidence	5/20.0 (25.0%)	7/20.0 (35.0%)	5/20.2 (24.8%)	6/20.0 (30.0%)
	Terminal Incidence	5/20 (25.0%)	7/20 (35.0%)	5/20 (25.0%)	6/20 (30.0%)
	Time-to-First	86 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.500	0.242	0.505	0.360
	Severity Profile	3 1 0 1	3 2 2 0	5 0 0 0	5 1 0 0
	JT/SW P-Value	0.227	0.121	0.263	0.279
	RTE P-Value	0.301	0.095	0.404	0.237
Pancreas * Inflammation	Simple Incidence	1/20 (5.0%)	3/20 (15.0%)	1/21 (4.8%)	2/20 (10.0%)
	Poly-K Incidence	1/20.0 (5.0%)	3/20.0 (15.0%)	1/20.2 (5.0%)	2/20.0 (10.0%)
	Terminal Incidence	1/20 (5.0%)	3/20 (15.0%)	1/20 (5.0%)	2/20 (10.0%)
	Time-to-First	86 (T)	85 (T)	90 (T)	85 (T)
	Poly-K P-Value	0.500N	0.500	0.497N	0.696
	Severity Profile	0 0 1 0	1 2 0 0	1 0 0 0	1 1 0 0
	JT/SW P-Value	0.292	0.331	0.466	0.505
	RTE P-Value	0.337N	0.278	0.300N	0.481
Pancreas * Infiltration Cellular	Simple Incidence	2/20 (10.0%)	2/20 (10.0%)	3/21 (14.3%)	3/20 (15.0%)
	Poly-K Incidence	2/20.0 (10.0%)	2/20.0 (10.0%)	3/20.2 (14.9%)	3/20.0 (15.0%)
	Terminal Incidence	2/20 (10.0%)	2/20 (10.0%)	3/20 (15.0%)	3/20 (15.0%)
	Time-to-First	90 (T)	89 (T)	86 (T)	86 (T)
	Poly-K P-Value	0.696	0.696	0.503	0.500
	Severity Profile	2 0 0 0	2 0 0 0	3 0 0 0	3 0 0 0
	JT/SW P-Value	0.592	0.612	0.453	0.431
	RTE P-Value	0.500	0.500	0.336	0.313

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Islets, Pancreatic * Fibrosis	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	1/18 (5.6%)	3/21 (14.3%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	1/18.0 (5.6%)	3/21.0 (14.3%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	1/18 (5.6%)	3/21 (14.3%)
	Time-to-First	----	----	90 (T)	90 (T)
	Poly-K P-Value	0.488	---	0.479	0.121
	Severity Profile	---	---	0 1 0 0	1 1 0 1
	JT/SW P-Value	0.454	0.500	0.107	0.021 * ¹
	RTE P-Value	0.467	0.500	0.126	0.006 **
Pituitary Gland * Cyst	Simple Incidence	3/20 (15.0%)	2/23 (8.7%)	3/18 (16.7%)	1/21 (4.8%)
	Poly-K Incidence	3/20.0 (15.0%)	2/23.0 (8.7%)	3/18.0 (16.7%)	1/21.0 (4.8%)
	Terminal Incidence	3/20 (15.0%)	2/23 (8.7%)	3/18 (16.7%)	1/21 (4.8%)
	Time-to-First	85 (T)	85 (T)	90 (T)	86 (T)
	Poly-K P-Value	0.093N	0.435N	0.617	0.284N
Thyroid Gland * Ultimobranhial Cyst	Simple Incidence	6/20 (30.0%)	5/23 (21.7%)	5/18 (27.8%)	5/21 (23.8%)
	Poly-K Incidence	6/20.0 (30.0%)	5/23.0 (21.7%)	5/18.0 (27.8%)	5/21.0 (23.8%)
	Terminal Incidence	6/20 (30.0%)	5/23 (21.7%)	5/18 (27.8%)	5/21 (23.8%)
	Time-to-First	89 (T)	90 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.131	0.396N	0.580N	0.463N
Thyroid Gland * Ectopic Thymus	Simple Incidence	0/20 (0.0%)	1/23 (4.3%)	1/18 (5.6%)	1/21 (4.8%)
	Poly-K Incidence	0/20.0 (0.0%)	1/23.0 (4.3%)	1/18.0 (5.6%)	1/21.0 (4.8%)
	Terminal Incidence	0/20 (0.0%)	1/23 (4.3%)	1/18 (5.6%)	1/21 (4.8%)
	Time-to-First	----	93 (T)	90 (T)	90 (T)
	Poly-K P-Value	0.522	0.528	0.479	0.510
Mammary Gland, Duct * Hyperplasia	Simple Incidence	0/20 (0.0%)	3/23 (13.0%)	0/18 (0.0%)	1/21 (4.8%)
	Poly-K Incidence	0/20.0 (0.0%)	3/23.0 (13.0%)	0/18.0 (0.0%)	1/21.0 (4.8%)
	Terminal Incidence	0/20 (0.0%)	3/23 (13.0%)	0/18 (0.0%)	1/21 (4.8%)
	Time-to-First	----	85 (T)	----	85 (T)
	Poly-K P-Value	0.493	0.139	---	0.510
	Severity Profile	---	3 0 0 0	---	1 0 0 0
	JT/SW P-Value	0.441	0.049 * ¹	0.180	0.218
	RTE P-Value	0.398	0.032 *	0.500	0.190
Mammary Gland, Alveolus * Hyperplasia	Simple Incidence	5/20 (25.0%)	3/23 (13.0%)	7/18 (38.9%)	5/21 (23.8%)
	Poly-K Incidence	5/20.0 (25.0%)	3/23.0 (13.0%)	7/18.0 (38.9%)	5/21.0 (23.8%)
	Terminal Incidence	5/20 (25.0%)	3/23 (13.0%)	7/18 (38.9%)	5/21 (23.8%)
	Time-to-First	85 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.128	0.273N	0.287	0.606N
	Severity Profile	4 1 0 0	2 1 0 0	7 0 0 0	5 0 0 0
	JT/SW P-Value	0.116	0.830	0.233	0.471
	RTE P-Value	0.131	0.207N	0.216	0.430N
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	5/20 (25.0%)	6/23 (26.1%)	7/18 (38.9%)	6/21 (28.6%)
	Poly-K Incidence	5/20.0 (25.0%)	6/23.0 (26.1%)	7/18.0 (38.9%)	6/21.0 (28.6%)
	Terminal Incidence	5/20 (25.0%)	6/23 (26.1%)	7/18 (38.9%)	6/21 (28.6%)
	Time-to-First	85 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.144	0.604	0.287	0.537
	Severity Profile	4 1 0 0	5 1 0 0	7 0 0 0	6 0 0 0
	JT/SW P-Value	0.092	0.474	0.255	0.409
	RTE P-Value	0.101	0.478	0.236	0.455

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		BPA 80	BPA 260	BPA 840	BPA 2700
Islets, Pancreatic * Fibrosis	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	0/21 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	0/20.2 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	----	----	90 (T)
	Poly-K P-Value	---	---	---	0.500
	Severity Profile	---	---	---	0 1 0 0
	JT/SW P-Value	0.154	0.251	0.302	0.250
	RTE P-Value	0.500	0.500	0.500	0.122
Pituitary Gland * Cyst	Simple Incidence	0/20 (0.0%)	2/20 (10.0%)	1/21 (4.8%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/20.0 (10.0%)	1/20.2 (5.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)	1/20 (5.0%)	1/20 (5.0%)
	Time-to-First	----	85 (T)	88 (T)	91 (T)
	Poly-K P-Value	0.111N	0.500N	0.298N	0.301N
Thyroid Gland * Ultimobranchial Cyst	Simple Incidence	5/20 (25.0%)	5/20 (25.0%)	5/21 (23.8%)	10/20 (50.0%)
	Poly-K Incidence	5/20.0 (25.0%)	5/20.0 (25.0%)	5/20.2 (24.8%)	10/20.0 (50.0%)
	Terminal Incidence	5/20 (25.0%)	5/20 (25.0%)	5/20 (25.0%)	10/20 (50.0%)
	Time-to-First	89 (T)	89 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.500N	0.500N	0.494N	0.168
Thyroid Gland * Ectopic Thymus	Simple Incidence	2/20 (10.0%)	0/20 (0.0%)	0/21 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	2/20.0 (10.0%)	0/20.0 (0.0%)	0/20.2 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	2/20 (10.0%)	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	90 (T)	----	----	92 (T)
	Poly-K P-Value	0.234	---	---	0.500
Mammary Gland, Duct * Hyperplasia	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	2/21 (9.5%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	2/21.0 (9.5%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)	1/20 (5.0%)
	Time-to-First	----	----	50	91 (T)
	Poly-K P-Value	---	---	0.245	0.500
	Severity Profile	---	---	1 1 0 0	0 1 0 0
	JT/SW P-Value	0.284	0.330	0.082	0.169
	RTE P-Value	0.500	0.500	0.040 *	0.126
Mammary Gland, Alveolus * Hyperplasia	Simple Incidence	7/20 (35.0%)	7/20 (35.0%)	4/21 (19.0%)	8/20 (40.0%)
	Poly-K Incidence	7/20.0 (35.0%)	7/20.0 (35.0%)	4/20.2 (19.9%)	8/20.0 (40.0%)
	Terminal Incidence	7/20 (35.0%)	7/20 (35.0%)	4/20 (20.0%)	8/20 (40.0%)
	Time-to-First	86 (T)	85 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.368	0.368	0.495N	0.252
	Severity Profile	3 4 0 0	6 0 1 0	3 1 0 0	6 2 0 0
	JT/SW P-Value	0.227	0.284	0.469	0.195
	RTE P-Value	0.183	0.251	0.346N	0.141
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	7/20 (35.0%)	7/20 (35.0%)	6/21 (28.6%)	9/20 (45.0%)
	Poly-K Incidence	7/20.0 (35.0%)	7/20.0 (35.0%)	6/21.0 (28.6%)	9/20.0 (45.0%)
	Terminal Incidence	7/20 (35.0%)	7/20 (35.0%)	5/20 (25.0%)	9/20 (45.0%)
	Time-to-First	86 (T)	85 (T)	50	85 (T)
	Poly-K P-Value	0.368	0.368	0.537	0.161
	Severity Profile	3 4 0 0	6 0 1 0	4 2 0 0	6 3 0 0
	JT/SW P-Value	0.227	0.288	0.359	0.100
	RTE P-Value	0.180	0.264	0.376	0.078

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Lymph Node, Mandibular * Hyperplasia	Simple Incidence	2/20 (10.0%)	1/23 (4.3%)	0/18 (0.0%)	1/21 (4.8%)
	Poly-K Incidence	2/20.0 (10.0%)	1/23.0 (4.3%)	0/18.0 (0.0%)	1/21.0 (4.8%)
	Terminal Incidence	2/20 (10.0%)	1/23 (4.3%)	0/18 (0.0%)	1/21 (4.8%)
	Time-to-First	89 (T)	85 (T)	----	85 (T)
	Poly-K P-Value	0.020N*	0.451N	0.258N	0.483N
	Severity Profile	0 1 0 1	0 0 0 1	---	0 0 1 0
	JT/SW P-Value	0.014N*	0.245N	0.095N	0.174N
	RTE P-Value	0.012N*	0.068N	0.050N*	0.064N
Epididymis * Hypospermia	Simple Incidence	1/20 (5.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	89 (T)	----	----	----
	Poly-K P-Value	0.365	0.472N	0.521N	0.490N
	Severity Profile	0 0 0 1	---	---	---
	JT/SW P-Value	0.335	0.858	0.939	0.977
	RTE P-Value	0.341	0.100N	0.077N	0.094N
Epididymis * Exfoliated Germ Cell	Simple Incidence	1/20 (5.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	89 (T)	----	----	----
	Poly-K P-Value	0.268	0.472N	0.521N	0.490N
	Severity Profile	1 0 0 0	---	---	---
	JT/SW P-Value	0.239	0.858	0.939	0.977
	RTE P-Value	0.237	0.188N	0.173N	0.188N
Preputial Gland * Inflammation	Simple Incidence	0/20 (0.0%)	1/23 (4.3%)	1/18 (5.6%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/23.0 (4.3%)	1/18.0 (5.6%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	1/23 (4.3%)	1/18 (5.6%)	0/21 (0.0%)
	Time-to-First	----	90 (T)	92 (T)	----
	Poly-K P-Value	0.065	0.528	0.479	---
	Severity Profile	---	0 0 0 1	0 1 0 0	---
	JT/SW P-Value	0.053	0.176	0.209	0.323
	RTE P-Value	0.052	0.194	0.211	0.500
Preputial Gland, Duct * Ectasia	Simple Incidence	0/20 (0.0%)	1/23 (4.3%)	1/18 (5.6%)	1/21 (4.8%)
	Poly-K Incidence	0/20.0 (0.0%)	1/23.0 (4.3%)	1/18.0 (5.6%)	1/21.0 (4.8%)
	Terminal Incidence	0/20 (0.0%)	1/23 (4.3%)	1/18 (5.6%)	1/21 (4.8%)
	Time-to-First	----	90 (T)	92 (T)	90 (T)
	Poly-K P-Value	0.066	0.528	0.479	0.510
	Severity Profile	---	0 0 0 1	0 0 1 0	0 1 0 0
	JT/SW P-Value	0.056	0.176	0.209	0.250
	RTE P-Value	0.054	0.263	0.233	0.264
Preputial Gland * Infiltration Cellular	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	1/21 (4.8%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	1/21.0 (4.8%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	1/21 (4.8%)
	Time-to-First	----	----	----	90 (T)
	Poly-K P-Value	0.516N	---	---	0.510
	Severity Profile	---	---	---	0 1 0 0
	JT/SW P-Value	0.415N	0.500N	0.583N	0.799N
	RTE P-Value	0.416N	0.500	0.500	0.063

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		BPA 80	BPA 260	BPA 840	BPA 2700
Lymph Node, Mandibular * Hyperplasia	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	0/21 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	0/20.2 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	----	----	----	----
	Poly-K P-Value	0.234N	0.234N	0.232N	0.234N
	Severity Profile	---	---	---	---
	JT/SW P-Value	0.068N	0.049N*	0.034N*	0.026N*
	RTE P-Value	0.048N*	0.049N*	0.048N*	0.047N*
Epididymis * Hypospermia	Simple Incidence	0/20 (0.0%)	2/20 (10.0%)	1/21 (4.8%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/20.0 (10.0%)	1/21.0 (4.8%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	----	89 (T)	50	----
	Poly-K P-Value	0.500N	0.500	0.749N	0.500N
	Severity Profile	---	0 1 0 1	0 0 1 0	---
	JT/SW P-Value	0.988	0.214	0.456	0.677
	RTE P-Value	0.083N	0.208	0.473N	0.080N
Epididymis * Exfoliated Germ Cell	Simple Incidence	0/20 (0.0%)	3/20 (15.0%)	1/21 (4.8%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	3/20.0 (15.0%)	1/21.0 (4.8%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	3/20 (15.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	----	89 (T)	50	----
	Poly-K P-Value	0.500N	0.301	0.749N	0.500N
	Severity Profile	---	1 2 0 0	0 1 0 0	---
	JT/SW P-Value	0.988	0.045 * ¹	0.270	0.519
	RTE P-Value	0.181N	0.012 *	0.493N	0.181N
Preputial Gland * Inflammation	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)	2/21 (9.5%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)	2/20.2 (9.9%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	2/20 (10.0%)	2/20 (10.0%)
	Time-to-First	----	89 (T)	85 (T)	89 (T)
	Poly-K P-Value	---	0.500	0.235	0.234
	Severity Profile	---	0 0 0 1	0 0 1 1	0 0 1 1
	JT/SW P-Value	0.383	0.206	0.064	0.079
	RTE P-Value	0.500	0.187	0.080	0.077
Preputial Gland, Duct * Ectasia	Simple Incidence	0/20 (0.0%)	2/20 (10.0%)	2/21 (9.5%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/20.0 (10.0%)	2/20.2 (9.9%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)	2/20 (10.0%)	2/20 (10.0%)
	Time-to-First	----	89 (T)	85 (T)	89 (T)
	Poly-K P-Value	---	0.234	0.235	0.234
	Severity Profile	---	0 0 1 1	0 1 0 1	0 0 1 1
	JT/SW P-Value	0.328	0.070	0.098	0.110
	RTE P-Value	0.500	0.090	0.114	0.084
Preputial Gland * Infiltration Cellular	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	0/21 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	0/20.2 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	----	----	----	----
	Poly-K P-Value	---	---	---	---
	Severity Profile	---	---	---	---
	JT/SW P-Value	0.636N	0.648N	0.656N	0.662N
	RTE P-Value	0.500	0.500	0.500	0.500

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Prostate * Atrophy	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	----	----	----	----
	Poly-K P-Value	0.204	---	---	---
	Severity Profile	---	---	---	---
	JT/SW P-Value	0.137	0.500	0.583	0.618
	RTE P-Value	0.180	0.500	0.500	0.500
Prostate * Inflammation	Simple Incidence	2/20 (10.0%)	2/23 (8.7%)	0/18 (0.0%)	1/21 (4.8%)
	Poly-K Incidence	2/20.0 (10.0%)	2/23.0 (8.7%)	0/18.0 (0.0%)	1/21.0 (4.8%)
	Terminal Incidence	2/20 (10.0%)	2/23 (8.7%)	0/18 (0.0%)	1/21 (4.8%)
	Time-to-First	90 (T)	90 (T)	----	90 (T)
	Poly-K P-Value	0.025 *	0.645N	0.258N	0.483N
	Severity Profile	2 0 0 0	2 0 0 0	---	1 0 0 0
	JT/SW P-Value	0.024 *	0.558	0.819	0.863
	RTE P-Value	0.023 *	0.446N	0.133N	0.297N
Prostate * Infiltration Cellular	Simple Incidence	17/20 (85.0%)	15/23 (65.2%)	14/18 (77.8%)	16/21 (76.2%)
	Poly-K Incidence	17/20.0 (85.0%)	15/23.0 (65.2%)	14/18.0 (77.8%)	16/21.0 (76.2%)
	Terminal Incidence	17/20 (85.0%)	15/23 (65.2%)	14/18 (77.8%)	16/21 (76.2%)
	Time-to-First	85 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.091	0.128N	0.440N	0.378N
	Severity Profile	8 7 2 0	5 8 2 0	6 8 0 0	10 5 1 0
	JT/SW P-Value	0.182	0.770	0.775	0.891
	RTE P-Value	0.185	0.226N	0.313N	0.137N
Testes, Germinal Epithelium * Degeneration	Simple Incidence	1/20 (5.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/23.0 (0.0%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/23 (0.0%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	89 (T)	----	----	----
	Poly-K P-Value	0.518N	0.472N	0.521N	0.490N
	Severity Profile	0 0 0 1	---	---	---
	JT/SW P-Value	0.446N	0.142N	0.136N	0.092N
	RTE P-Value	0.445N	0.044N*	0.037N*	0.044N*
Testes, Seminiferous Tubule * Giant Cell	Simple Incidence	0/20 (0.0%)	5/23 (21.7%)	1/18 (5.6%)	4/21 (19.0%)
	Poly-K Incidence	0/20.0 (0.0%)	5/23.0 (21.7%)	1/18.0 (5.6%)	4/21.0 (19.0%)
	Terminal Incidence	0/20 (0.0%)	5/23 (21.7%)	1/18 (5.6%)	4/21 (19.0%)
	Time-to-First	----	85 (T)	86 (T)	86 (T)
	Poly-K P-Value	0.453	0.035 *	0.479	0.058
	Severity Profile	---	5 0 0 0	1 0 0 0	4 0 0 0
	JT/SW P-Value	0.441	0.014 * ¹	0.078	0.039 * ¹
	RTE P-Value	0.393	0.012 *	0.293	0.022 *
Kidney * Cyst	Simple Incidence	9/20 (45.0%)	9/23 (39.1%)	5/18 (27.8%)	8/21 (38.1%)
	Poly-K Incidence	9/20.0 (45.0%)	9/23.0 (39.1%)	5/18.0 (27.8%)	8/21.0 (38.1%)
	Terminal Incidence	9/20 (45.0%)	9/23 (39.1%)	5/18 (27.8%)	8/21 (38.1%)
	Time-to-First	86 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.343N	0.469N	0.225N	0.449N
	Severity Profile	6 3 0 0	4 5 0 0	2 3 0 0	4 4 0 0
	JT/SW P-Value	0.429N	0.451N	0.244N	0.377N
	RTE P-Value	0.440N	0.441N	0.212N	0.398N

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		BPA 80	BPA 260	BPA 840	BPA 2700
Prostate * Atrophy	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	1/21 (4.8%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	1/20.2 (5.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)	0/20 (0.0%)
	Time-to-First	----	----	91 (T)	----
	Poly-K P-Value	---	---	0.501	---
	Severity Profile	---	---	0 1 0 0	---
	JT/SW P-Value	0.636	0.648	0.043 * ¹	0.224
	RTE P-Value	0.500	0.500	0.063	0.500
Prostate * Inflammation	Simple Incidence	2/20 (10.0%)	3/20 (15.0%)	3/21 (14.3%)	5/20 (25.0%)
	Poly-K Incidence	2/20.0 (10.0%)	3/20.0 (15.0%)	3/20.2 (14.9%)	5/20.0 (25.0%)
	Terminal Incidence	2/20 (10.0%)	3/20 (15.0%)	3/20 (15.0%)	5/20 (25.0%)
	Time-to-First	86 (T)	89 (T)	85 (T)	87 (T)
	Poly-K P-Value	0.696	0.500	0.503	0.204
	Severity Profile	2 0 0 0	3 0 0 0	3 0 0 0	5 0 0 0
	JT/SW P-Value	0.636	0.382	0.416	0.087
	RTE P-Value	0.500	0.307	0.331	0.068
Prostate * Infiltration Cellular	Simple Incidence	14/20 (70.0%)	16/20 (80.0%)	18/21 (85.7%)	18/20 (90.0%)
	Poly-K Incidence	14/20.0 (70.0%)	16/20.0 (80.0%)	18/20.2 (89.3%)	18/20.0 (90.0%)
	Terminal Incidence	14/20 (70.0%)	16/20 (80.0%)	18/20 (90.0%)	18/20 (90.0%)
	Time-to-First	86 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.227N	0.500N	0.524	0.500
	Severity Profile	7 4 3 0	6 7 3 0	8 9 1 0	7 11 0 0
	JT/SW P-Value	0.901	0.585	0.623	0.512
	RTE P-Value	0.223N	0.434	0.500N	0.375
Testes, Germinal Epithelium * Degeneration	Simple Incidence	0/20 (0.0%)	2/20 (10.0%)	0/21 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/20.0 (10.0%)	0/20.2 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	----	89 (T)	----	----
	Poly-K P-Value	0.500N	0.500	0.499N	0.500N
	Severity Profile	---	0 0 1 1	---	---
	JT/SW P-Value	0.070N	0.359N	0.178N	0.163N
	RTE P-Value	0.040N*	0.137	0.044N*	0.039N*
Testes, Seminiferous Tubule * Giant Cell	Simple Incidence	2/20 (10.0%)	2/20 (10.0%)	1/21 (4.8%)	3/20 (15.0%)
	Poly-K Incidence	2/20.0 (10.0%)	2/20.0 (10.0%)	1/20.2 (5.0%)	3/20.0 (15.0%)
	Terminal Incidence	2/20 (10.0%)	2/20 (10.0%)	1/20 (5.0%)	3/20 (15.0%)
	Time-to-First	90 (T)	85 (T)	90 (T)	86 (T)
	Poly-K P-Value	0.234	0.234	0.501	0.111
	Severity Profile	2 0 0 0	2 0 0 0	1 0 0 0	3 0 0 0
	JT/SW P-Value	0.098	0.115	0.137	0.087
	RTE P-Value	0.138	0.142	0.314	0.063
Kidney * Cyst	Simple Incidence	8/20 (40.0%)	6/20 (30.0%)	8/21 (38.1%)	7/20 (35.0%)
	Poly-K Incidence	8/20.0 (40.0%)	6/20.0 (30.0%)	8/20.2 (39.7%)	7/20.0 (35.0%)
	Terminal Incidence	8/20 (40.0%)	6/20 (30.0%)	8/20 (40.0%)	7/20 (35.0%)
	Time-to-First	86 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.500N	0.260N	0.492N	0.376N
	Severity Profile	2 5 1 0	4 2 0 0	3 4 1 0	2 5 0 0
	JT/SW P-Value	0.507N	0.253N	0.430N	0.469N
	RTE P-Value	0.441	0.197N	0.465N	0.391N

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 2.5	BPA 8.0	BPA 25
Kidney, Cortex * Cyst	Simple Incidence	1/20 (5.0%)	2/23 (8.7%)	3/18 (16.7%)	1/21 (4.8%)
	Poly-K Incidence	1/20.0 (5.0%)	2/23.0 (8.7%)	3/18.0 (16.7%)	1/21.0 (4.8%)
	Terminal Incidence	1/20 (5.0%)	2/23 (8.7%)	3/18 (16.7%)	1/21 (4.8%)
	Time-to-First	91 (T)	90 (T)	85 (T)	90 (T)
	Poly-K P-Value	0.293	0.549	0.263	0.749N
	Severity Profile	1 0 0 0	2 0 0 0	1 2 0 0	0 1 0 0
	JT/SW P-Value	0.245	0.320	0.122	0.329
	RTE P-Value	0.265	0.353	0.109	0.492
Kidney, Renal Tubule * Cyst	Simple Incidence	8/20 (40.0%)	7/23 (30.4%)	2/18 (11.1%)	7/21 (33.3%)
	Poly-K Incidence	8/20.0 (40.0%)	7/23.0 (30.4%)	2/18.0 (11.1%)	7/21.0 (33.3%)
	Terminal Incidence	8/20 (40.0%)	7/23 (30.4%)	2/18 (11.1%)	7/21 (33.3%)
	Time-to-First	86 (T)	85 (T)	90 (T)	85 (T)
	Poly-K P-Value	0.377N	0.371N	0.045N*	0.454N
	Severity Profile	5 3 0 0	2 5 0 0	1 1 0 0	4 3 0 0
	JT/SW P-Value	0.370N	0.359N	0.039N* ¹	0.175N
	RTE P-Value	0.389N	0.335N	0.038N*	0.345N
Kidney * Hydronephrosis	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)	0/21 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/23.0 (8.7%)	0/18.0 (0.0%)	0/21.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)	0/21 (0.0%)
	Time-to-First	----	85 (T)	----	----
	Poly-K P-Value	0.077	0.267	---	---
	Severity Profile	---	2 0 0 0	---	---
	JT/SW P-Value	0.072	0.091	0.241	0.323
	RTE P-Value	0.058	0.111	0.500	0.500
Kidney * Nephropathy	Simple Incidence	14/20 (70.0%)	17/23 (73.9%)	15/18 (83.3%)	16/21 (76.2%)
	Poly-K Incidence	14/20.0 (70.0%)	17/23.0 (73.9%)	15/18.0 (83.3%)	16/21.0 (76.2%)
	Terminal Incidence	14/20 (70.0%)	17/23 (73.9%)	15/18 (83.3%)	16/21 (76.2%)
	Time-to-First	85 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.252	0.522	0.283	0.463
	Severity Profile	14 0 0 0	13 4 0 0	14 1 0 0	14 2 0 0
	JT/SW P-Value	0.262	0.146	0.172	0.196
	RTE P-Value	0.265	0.110	0.146	0.182

Table 4: Effect of Low Level Exposures to BPA on Non-neoplasm Incidence in Males

		BPA 80	BPA 260	BPA 840	BPA 2700
Kidney, Cortex * Cyst	Simple Incidence	2/20 (10.0%)	2/20 (10.0%)	3/21 (14.3%)	2/20 (10.0%)
	Poly-K Incidence	2/20.0 (10.0%)	2/20.0 (10.0%)	3/20.2 (14.9%)	2/20.0 (10.0%)
	Terminal Incidence	2/20 (10.0%)	2/20 (10.0%)	3/20 (15.0%)	2/20 (10.0%)
	Time-to-First	90 (T)	89 (T)	85 (T)	87 (T)
	Poly-K P-Value	0.500	0.500	0.304	0.500
	Severity Profile	1 0 1 0	1 1 0 0	0 2 1 0	1 1 0 0
	JT/SW P-Value	0.356	0.370	0.186	0.285
	RTE P-Value	0.286	0.296	0.104	0.296
Kidney, Renal Tubule * Cyst	Simple Incidence	7/20 (35.0%)	5/20 (25.0%)	7/21 (33.3%)	5/20 (25.0%)
	Poly-K Incidence	7/20.0 (35.0%)	5/20.0 (25.0%)	7/20.2 (34.7%)	5/20.0 (25.0%)
	Terminal Incidence	7/20 (35.0%)	5/20 (25.0%)	7/20 (35.0%)	5/20 (25.0%)
	Time-to-First	86 (T)	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.500N	0.252N	0.493N	0.252N
	Severity Profile	2 5 0 0	4 1 0 0	4 3 0 0	1 4 0 0
	JT/SW P-Value	0.314N	0.191N	0.315N	0.309N
	RTE P-Value	0.465N	0.144N	0.345N	0.224N
Kidney * Hydronephrosis	Simple Incidence	3/20 (15.0%)	2/20 (10.0%)	0/21 (0.0%)	3/20 (15.0%)
	Poly-K Incidence	3/20.0 (15.0%)	2/20.0 (10.0%)	0/20.2 (0.0%)	3/20.0 (15.0%)
	Terminal Incidence	3/20 (15.0%)	2/20 (10.0%)	0/20 (0.0%)	3/20 (15.0%)
	Time-to-First	86 (T)	85 (T)	----	85 (T)
	Poly-K P-Value	0.111	0.234	---	0.111
	Severity Profile	2 0 1 0	1 1 0 0	---	2 0 1 0
	JT/SW P-Value	0.016 * ¹	0.056	0.151	0.030 *
	RTE P-Value	0.021 *	0.068	0.500	0.019 *
Kidney * Nephropathy	Simple Incidence	17/20 (85.0%)	18/20 (90.0%)	19/21 (90.5%)	13/20 (65.0%)
	Poly-K Incidence	17/20.0 (85.0%)	18/20.0 (90.0%)	19/21.0 (90.5%)	13/20.0 (65.0%)
	Terminal Incidence	17/20 (85.0%)	18/20 (90.0%)	18/20 (90.0%)	13/20 (65.0%)
	Time-to-First	86 (T)	85 (T)	50	86 (T)
	Poly-K P-Value	0.227	0.116	0.102	0.500N
	Severity Profile	16 1 0 0	17 1 0 0	16 2 0 1	12 1 0 0
	JT/SW P-Value	0.152	0.076	0.018 * ¹	0.154
	RTE P-Value	0.111	0.057	0.019 *	0.481N

Table 5: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 100K	BPA 300K
Heart * Cardiomyopathy	Simple Incidence	0/20 (0.0%)	1/21 (4.8%)	0/19 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.5 (4.9%)	0/19.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	0/19 (0.0%)
	Time-to-First	----	87 (T)	----
	Poly-K P-Value	0.726	0.505	---
	Severity Profile	---	1 0 0 0	---
	JT/SW P-Value	0.488	0.165	0.326
	RTE P-Value	0.500	0.177	0.500
Liver * Infiltration Cellular	Simple Incidence	0/20 (0.0%)	0/21 (0.0%)	1/19 (5.3%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.5 (0.0%)	1/19.0 (5.3%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/19 (5.3%)
	Time-to-First	----	----	90 (T)
	Poly-K P-Value	0.260	---	0.490
	Severity Profile	---	---	1 0 0 0
	JT/SW P-Value	0.105	0.500	0.120
	RTE P-Value	0.157	0.500	0.157
Liver * Granuloma	Simple Incidence	2/20 (10.0%)	0/21 (0.0%)	1/19 (5.3%)
	Poly-K Incidence	2/20.0 (10.0%)	0/20.5 (0.0%)	1/19.0 (5.3%)
	Terminal Incidence	2/20 (10.0%)	0/20 (0.0%)	1/19 (5.3%)
	Time-to-First	90 (T)	----	95 (T)
	Poly-K P-Value	0.372N	0.229N	0.518N
	Severity Profile	2 0 0 0	---	1 0 0 0
	JT/SW P-Value	0.241N	0.071N	0.171N
	RTE P-Value	0.252N	0.079N	0.252N
Pancreas, Acinar Cell * Atrophy	Simple Incidence	4/20 (20.0%)	1/21 (4.8%)	2/19 (10.5%)
	Poly-K Incidence	4/20.0 (20.0%)	1/20.5 (4.9%)	2/19.0 (10.5%)
	Terminal Incidence	4/20 (20.0%)	1/20 (5.0%)	2/19 (10.5%)
	Time-to-First	85 (T)	91 (T)	85 (T)
	Poly-K P-Value	0.247N	0.162N	0.356N
	Severity Profile	2 2 0 0	0 1 0 0	1 1 0 0
	JT/SW P-Value	0.177N	0.077N	0.142N
	RTE P-Value	0.212N	0.093N	0.212N
Pituitary Gland * Cyst	Simple Incidence	1/20 (5.0%)	0/21 (0.0%)	2/19 (10.5%)
	Poly-K Incidence	1/20.0 (5.0%)	0/20.5 (0.0%)	2/19.0 (10.5%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)	2/19 (10.5%)
	Time-to-First	88 (T)	----	93 (T)
	Poly-K P-Value	0.344	0.495N	0.482
Thyroid Gland * Ultimobranchial Cyst	Simple Incidence	6/20 (30.0%)	8/21 (38.1%)	10/19 (52.6%)
	Poly-K Incidence	6/20.0 (30.0%)	8/20.5 (39.1%)	10/19.0 (52.6%)
	Terminal Incidence	6/20 (30.0%)	8/20 (40.0%)	10/19 (52.6%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.102	0.393	0.133
Thyroid Gland * Ectopic Thymus	Simple Incidence	0/20 (0.0%)	0/21 (0.0%)	1/19 (5.3%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.5 (0.0%)	1/19.0 (5.3%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/19 (5.3%)
	Time-to-First	----	----	85 (T)
	Poly-K P-Value	0.260	---	0.490

Table 5: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 100K	BPA 300K
Mammary Gland, Duct * Hyperplasia	Simple Incidence	7/20 (35.0%)	13/21 (61.9%)	14/19 (73.7%)
	Poly-K Incidence	7/20.0 (35.0%)	13/20.5 (63.5%)	14/19.0 (73.7%)
	Terminal Incidence	7/20 (35.0%)	13/20 (65.0%)	14/19 (73.7%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.009 **	0.063	0.013 *
	Severity Profile	7 0 0 0	8 5 0 0	13 1 0 0
	JT/SW P-Value	0.014 *	0.016 *	0.014 *
	RTE P-Value	0.012 *	0.010 *	0.012 *
Mammary Gland, Alveolus * Hyperplasia	Simple Incidence	6/20 (30.0%)	3/21 (14.3%)	4/19 (21.1%)
	Poly-K Incidence	6/20.0 (30.0%)	3/20.5 (14.7%)	4/19.0 (21.1%)
	Terminal Incidence	6/20 (30.0%)	3/20 (15.0%)	4/19 (21.1%)
	Time-to-First	85 (T)	87 (T)	85 (T)
	Poly-K P-Value	0.311N	0.215N	0.395N
	Severity Profile	5 1 0 0	1 2 0 0	4 0 0 0
	JT/SW P-Value	0.236N	0.152N	0.224N
	RTE P-Value	0.240N	0.146N	0.240N
Mammary Gland, Alveolus * Hyperplasia (adjusted for pseudo-pregnancy)	Simple Incidence	5/17 (29.4%)	3/21 (14.3%)	4/19 (21.1%)
	Poly-K Incidence	5/17.0 (29.4%)	3/20.5 (14.7%)	4/19.0 (21.1%)
	Terminal Incidence	5/17 (29.4%)	3/20 (15.0%)	4/19 (21.1%)
	Time-to-First	85 (T)	87 (T)	85 (T)
	Poly-K P-Value	0.354N	0.245N	0.425N
	Severity Profile	4 1 0 0	1 2 0 0	4 0 0 0
	JT/SW P-Value	0.271N	0.166N	0.243N
	RTE P-Value	0.257N	0.169N	0.257N
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	11/20 (55.0%)	14/21 (66.7%)	15/19 (78.9%)
	Poly-K Incidence	11/20.0 (55.0%)	14/20.5 (68.4%)	15/19.0 (78.9%)
	Terminal Incidence	11/20 (55.0%)	14/20 (70.0%)	15/19 (78.9%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.076	0.291	0.105
	Severity Profile	10 1 0 0	8 6 0 0	14 1 0 0
	JT/SW P-Value	0.112	0.077	0.095
	RTE P-Value	0.107	0.053	0.107
Mammary Gland, Duct or Alveolus * Hyperplasia (adjusted for pseudo-pregnancy)	Simple Incidence	11/19 (57.9%)	14/21 (66.7%)	15/19 (78.9%)
	Poly-K Incidence	11/19.0 (57.9%)	14/20.5 (68.4%)	15/19.0 (78.9%)
	Terminal Incidence	11/19 (57.9%)	14/20 (70.0%)	15/19 (78.9%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.111	0.363	0.148
	Severity Profile	10 1 0 0	8 6 0 0	14 1 0 0
	JT/SW P-Value	0.153	0.101	0.129
	RTE P-Value	0.141	0.087	0.141
Ovary * Cyst	Simple Incidence	4/20 (20.0%)	1/21 (4.8%)	15/19 (78.9%)
	Poly-K Incidence	4/20.0 (20.0%)	1/20.5 (4.9%)	15/19.0 (78.9%)
	Terminal Incidence	4/20 (20.0%)	1/20 (5.0%)	15/19 (78.9%)
	Time-to-First	85 (T)	87 (T)	85 (T)
	Poly-K P-Value	<.001 ***	0.162N	<.001 ***

Table 5: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 100K	BPA 300K
Ovary, Corpus Luteum * Cyst	Simple Incidence	0/20 (0.0%)	1/21 (4.8%)	1/19 (5.3%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.5 (4.9%)	1/19.0 (5.3%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	1/19 (5.3%)
	Time-to-First	----	87 (T)	86 (T)
	Poly-K P-Value	0.320	0.505	0.490
Ovary, Follicle * Cyst	Simple Incidence	4/20 (20.0%)	0/21 (0.0%)	14/19 (73.7%)
	Poly-K Incidence	4/20.0 (20.0%)	0/20.5 (0.0%)	14/19.0 (73.7%)
	Terminal Incidence	4/20 (20.0%)	0/20 (0.0%)	14/19 (73.7%)
	Time-to-First	85 (T)	----	85 (T)
	Poly-K P-Value	<.001 ***	0.048N*	<.001 ***
	Severity Profile	0 4 0 0	---	1 5 4 4
	JT/SW P-Value	<.001 ***	0.983	<.001 ***
	RTE P-Value	<.001 ***	0.058N	<.001 ***
Ovary, Rete Ovarii * Cyst	Simple Incidence	1/20 (5.0%)	0/21 (0.0%)	0/19 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/20.5 (0.0%)	0/19.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)	0/19 (0.0%)
	Time-to-First	95 (T)	----	----
	Poly-K P-Value	0.275N	0.495N	0.510N
Ovary, Corpus Luteum * Hypertrophy	Simple Incidence	4/20 (20.0%)	1/21 (4.8%)	1/19 (5.3%)
	Poly-K Incidence	4/20.0 (20.0%)	1/20.5 (4.9%)	1/19.0 (5.3%)
	Terminal Incidence	4/20 (20.0%)	1/20 (5.0%)	1/19 (5.3%)
	Time-to-First	85 (T)	88 (T)	95 (T)
	Poly-K P-Value	0.099N	0.162N	0.185N
Ovary, Corpus Luteum * Depletion	Simple Incidence	0/20 (0.0%)	1/21 (4.8%)	14/19 (73.7%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.5 (4.9%)	14/19.0 (73.7%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	14/19 (73.7%)
	Time-to-First	----	88 (T)	85 (T)
	Poly-K P-Value	<.001 ***	0.505	<.001 ***
	Severity Profile	---	0 1 0 0	3 6 4 1
	JT/SW P-Value	<.001 ***	0.165	<.001 ***
	RTE P-Value	<.001 ***	0.308	<.001 ***
Ovary, Antral Follicles * Depletion	Simple Incidence	3/20 (15.0%)	2/21 (9.5%)	10/19 (52.6%)
	Poly-K Incidence	3/20.0 (15.0%)	2/20.5 (9.8%)	10/19.0 (52.6%)
	Terminal Incidence	3/20 (15.0%)	2/20 (10.0%)	10/19 (52.6%)
	Time-to-First	85 (T)	88 (T)	85 (T)
	Poly-K P-Value	0.003 **	0.489N	0.011 *
Uterus, Endometrium * Vacuolization Cytoplasmic	Simple Incidence	3/20 (15.0%)	0/21 (0.0%)	0/19 (0.0%)
	Poly-K Incidence	3/20.0 (15.0%)	0/20.5 (0.0%)	0/19.0 (0.0%)
	Terminal Incidence	3/20 (15.0%)	0/20 (0.0%)	0/19 (0.0%)
	Time-to-First	85 (T)	----	----
	Poly-K P-Value	0.032N*	0.107N	0.120N

Table 5: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 100K	BPA 300K
Uterus, Endometrium *	Simple Incidence	0/20 (0.0%)	1/21 (4.8%)	0/19 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.5 (4.9%)	0/19.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	0/19 (0.0%)
	Time-to-First	----	87 (T)	----
	Poly-K P-Value	0.726	0.505	---
	Severity Profile	---	0 1 0 0	---
	JT/SW P-Value	0.488	0.165	0.326
	RTE P-Value	0.500	0.179	0.500
Uterus, Endometrium *	Simple Incidence	1/20 (5.0%)	3/21 (14.3%)	7/19 (36.8%)
	Poly-K Incidence	1/20.0 (5.0%)	3/20.5 (14.7%)	7/19.0 (36.8%)
	Terminal Incidence	1/20 (5.0%)	3/20 (15.0%)	7/19 (36.8%)
	Time-to-First	88 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.007 **	0.310	0.014 *
	Severity Profile	0 1 0 0	3 0 0 0	3 4 0 0
	JT/SW P-Value	0.005 **	0.181	0.006 **
	RTE P-Value	0.004 **	0.259	0.004 **
Uterus, Endometrium *	Simple Incidence	0/20 (0.0%)	0/21 (0.0%)	1/19 (5.3%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.5 (0.0%)	1/19.0 (5.3%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/19 (5.3%)
	Time-to-First	----	----	95 (T)
	Poly-K P-Value	0.260	---	0.490
	Severity Profile	---	---	0 0 0 1
	JT/SW P-Value	0.105	0.500	0.120
	RTE P-Value	0.157	0.500	0.157
Uterus, Endometrium *	Simple Incidence	1/20 (5.0%)	4/21 (19.0%)	2/19 (10.5%)
	Poly-K Incidence	1/20.0 (5.0%)	4/20.5 (19.6%)	2/19.0 (10.5%)
	Terminal Incidence	1/20 (5.0%)	4/20 (20.0%)	2/19 (10.5%)
	Time-to-First	88 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.380	0.177	0.482
	Severity Profile	1 0 0 0	4 0 0 0	2 0 0 0
	JT/SW P-Value	0.287	0.087	0.200
	RTE P-Value	0.298	0.096	0.298
Vagina, Mucocyte *	Simple Incidence	3/20 (15.0%)	0/21 (0.0%)	1/19 (5.3%)
	Poly-K Incidence	3/20.0 (15.0%)	0/20.5 (0.0%)	1/19.0 (5.3%)
	Terminal Incidence	3/20 (15.0%)	0/20 (0.0%)	1/19 (5.3%)
	Time-to-First	85 (T)	----	95 (T)
	Poly-K P-Value	0.177N	0.107N	0.320N
Kidney, Renal Tubule *	Simple Incidence	14/20 (70.0%)	16/21 (76.2%)	14/19 (73.7%)
	Poly-K Incidence	14/20.0 (70.0%)	16/20.5 (78.2%)	14/19.0 (73.7%)
	Terminal Incidence	14/20 (70.0%)	16/20 (80.0%)	14/19 (73.7%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.466	0.407	0.539
	Severity Profile	11 3 0 0	14 2 0 0	8 5 1 0
	JT/SW P-Value	0.173	0.464	0.206
	RTE P-Value	0.177	0.473	0.177

Table 5: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Females

		Vehicle Controls	BPA 100K	BPA 300K
Kidney, Renal Tubule * Cyst	Simple Incidence	1/20 (5.0%)	8/21 (38.1%)	12/19 (63.2%)
	Poly-K Incidence	1/20.0 (5.0%)	8/20.5 (39.1%)	12/19.0 (63.2%)
	Terminal Incidence	1/20 (5.0%)	8/20 (40.0%)	12/19 (63.2%)
	Time-to-First	88 (T)	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	0.009 **	<.001 ***
	Severity Profile	1 0 0 0	7 1 0 0	5 3 3 1
	JT/SW P-Value	<.001 ***	0.006 **	<.001 ***
		RTE P-Value	<.001 ***	0.014 *
Kidney * Nephropathy	Simple Incidence	12/20 (60.0%)	13/21 (61.9%)	12/19 (63.2%)
	Poly-K Incidence	12/20.0 (60.0%)	13/21.0 (61.9%)	12/19.0 (63.2%)
	Terminal Incidence	12/20 (60.0%)	12/20 (60.0%)	12/19 (63.2%)
	Time-to-First	85 (T)	71	85 (T)
	Poly-K P-Value	0.485	0.576	0.549
	Severity Profile	12 0 0 0	11 1 0 1	12 0 0 0
	JT/SW P-Value	0.422	0.317	0.435
		RTE P-Value	0.426	0.315

Table 6: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 100K	BPA 300K
Heart * Cardiomyopathy	Simple Incidence	7/20 (35.0%)	10/23 (43.5%)	2/18 (11.1%)
	Poly-K Incidence	7/20.0 (35.0%)	10/21.1 (47.3%)	2/18.0 (11.1%)
	Terminal Incidence	7/20 (35.0%)	10/20 (50.0%)	2/18 (11.1%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.080N	0.316	0.086N
	Severity Profile	6 1 0 0	9 1 0 0	2 0 0 0
	JT/SW P-Value	0.061N	0.695N	0.062N
	RTE P-Value	0.053N	0.285	0.053N
Liver * Hepatodiaphragmatic Nodule	Simple Incidence	1/20 (5.0%)	3/23 (13.0%)	2/18 (11.1%)
	Poly-K Incidence	1/20.0 (5.0%)	3/21.1 (14.2%)	2/18.0 (11.1%)
	Terminal Incidence	1/20 (5.0%)	3/20 (15.0%)	2/18 (11.1%)
	Time-to-First	90 (T)	91 (T)	88 (T)
	Poly-K P-Value	0.354	0.322	0.463
	Severity Profile			
	JT/SW P-Value			
Pancreas, Acinus * Degeneration	Simple Incidence	4/20 (20.0%)	3/23 (13.0%)	2/18 (11.1%)
	Poly-K Incidence	4/20.0 (20.0%)	3/21.1 (14.2%)	2/18.0 (11.1%)
	Terminal Incidence	4/20 (20.0%)	3/20 (15.0%)	2/18 (11.1%)
	Time-to-First	90 (T)	89 (T)	85 (T)
	Poly-K P-Value	0.295N	0.468N	0.383N
	Severity Profile	4 0 0 0	2 1 0 0	2 0 0 0
	JT/SW P-Value	0.225N	0.297N	0.270N
	RTE P-Value	0.230N	0.289N	0.230N
Pancreas * Inflammation	Simple Incidence	2/20 (10.0%)	1/23 (4.3%)	0/18 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	1/21.1 (4.7%)	0/18.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	1/20 (5.0%)	0/18 (0.0%)
	Time-to-First	90 (T)	89 (T)	----
	Poly-K P-Value	0.149N	0.480N	0.258N
	Severity Profile	2 0 0 0	0 1 0 0	---
	JT/SW P-Value	0.084N	0.254N	0.097N
	RTE P-Value	0.125N	0.213N	0.125N
Pancreas * Infiltration Cellular	Simple Incidence	2/20 (10.0%)	1/23 (4.3%)	2/18 (11.1%)
	Poly-K Incidence	2/20.0 (10.0%)	1/21.1 (4.7%)	2/18.0 (11.1%)
	Terminal Incidence	2/20 (10.0%)	1/20 (5.0%)	2/18 (11.1%)
	Time-to-First	90 (T)	90 (T)	85 (T)
	Poly-K P-Value	0.576	0.480N	0.658
	Severity Profile	2 0 0 0	1 0 0 0	2 0 0 0
	JT/SW P-Value	0.467	0.763	0.530
	RTE P-Value	0.452	0.256N	0.452
Pituitary Gland * Cyst	Simple Incidence	3/20 (15.0%)	1/23 (4.3%)	1/18 (5.6%)
	Poly-K Incidence	3/20.0 (15.0%)	1/21.1 (4.7%)	1/18.0 (5.6%)
	Terminal Incidence	3/20 (15.0%)	1/20 (5.0%)	1/18 (5.6%)
	Time-to-First	85 (T)	89 (T)	85 (T)
	Poly-K P-Value	0.218N	0.281N	0.340N
	Severity Profile			
	JT/SW P-Value			
Thyroid Gland * Ultimobranchial Cyst	Simple Incidence	6/20 (30.0%)	6/23 (26.1%)	5/18 (27.8%)
	Poly-K Incidence	6/20.0 (30.0%)	6/21.7 (27.7%)	5/18.0 (27.8%)
	Terminal Incidence	6/20 (30.0%)	5/20 (25.0%)	5/18 (27.8%)
	Time-to-First	89 (T)	73	85 (T)
	Poly-K P-Value	0.510N	0.569N	0.580N
	Severity Profile			
	JT/SW P-Value			

Table 6: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 100K	BPA 300K
Thyroid Gland * Ectopic Thymus	Simple Incidence	0/20 (0.0%)	1/23 (4.3%)	0/18 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/21.1 (4.7%)	0/18.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	0/18 (0.0%)
	Time-to-First	----	89 (T)	----
	Poly-K P-Value	0.724	0.511	---
Mammary Gland, Duct * Hyperplasia	Simple Incidence	0/20 (0.0%)	1/23 (4.3%)	1/18 (5.6%)
	Poly-K Incidence	0/20.0 (0.0%)	1/21.9 (4.6%)	1/18.0 (5.6%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/18 (5.6%)
	Time-to-First	----	56	85 (T)
	Poly-K P-Value	0.306	0.518	0.479
Mammary Gland, Alveolus * Hyperplasia	Severity Profile	---	1 0 0 0	1 0 0 0
	JT/SW P-Value	0.166	0.176	0.204
	RTE P-Value	0.190	0.218	0.190
	Simple Incidence	5/20 (25.0%)	10/23 (43.5%)	6/18 (33.3%)
	Poly-K Incidence	5/20.0 (25.0%)	10/22.2 (45.0%)	6/18.0 (33.3%)
Mammary Gland, Duct or Alveolus * Hyperplasia	Terminal Incidence	5/20 (25.0%)	8/20 (40.0%)	6/18 (33.3%)
	Time-to-First	85 (T)	73	85 (T)
	Poly-K P-Value	0.342	0.150	0.420
	Severity Profile	4 1 0 0	7 2 1 0	3 3 0 0
	JT/SW P-Value	0.222	0.094	0.190
Lymph Node, Mandibular * Hyperplasia	RTE P-Value	0.242	0.098	0.242
	Simple Incidence	5/20 (25.0%)	11/23 (47.8%)	7/18 (38.9%)
	Poly-K Incidence	5/20.0 (25.0%)	11/23.0 (47.8%)	7/18.0 (38.9%)
	Terminal Incidence	5/20 (25.0%)	8/20 (40.0%)	7/18 (38.9%)
	Time-to-First	85 (T)	56	85 (T)
Lung * Inflammation	Poly-K P-Value	0.226	0.109	0.287
	Severity Profile	4 1 0 0	8 2 1 0	4 3 0 0
	JT/SW P-Value	0.140	0.059	0.123
	RTE P-Value	0.163	0.066	0.163
	Simple Incidence	2/20 (10.0%)	0/23 (0.0%)	0/18 (0.0%)
Lymph Node, Mandibular * Hyperplasia	Poly-K Incidence	2/20.0 (10.0%)	0/21.1 (0.0%)	0/18.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	0/20 (0.0%)	0/18 (0.0%)
	Time-to-First	89 (T)	----	----
	Poly-K P-Value	0.094N	0.221N	0.258N
	Severity Profile	0 1 0 1	---	---
Lung * Inflammation	JT/SW P-Value	0.039N*	0.062N	0.050N
	RTE P-Value	0.049N*	0.049N*	0.049N*
	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/22.5 (8.9%)	0/18.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	0/18 (0.0%)
Lung * Inflammation	Time-to-First	----	56	----
	Poly-K P-Value	0.655	0.261	---
	Severity Profile	---	1 0 1 0	---
	JT/SW P-Value	0.466	0.091	0.241
	RTE P-Value	0.500	0.071	0.500

Table 6: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 100K	BPA 300K
Epididymis * Hypospermia	Simple Incidence	1/20 (5.0%)	1/23 (4.3%)	0/18 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	1/21.9 (4.6%)	0/18.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)	0/18 (0.0%)
	Time-to-First	89 (T)	56	----
	Poly-K P-Value	0.349N	0.740N	0.521N
	Severity Profile	0 0 0 1	0 1 0 0	---
	JT/SW P-Value	0.195N	0.447N	0.229N
	RTE P-Value	0.165N	0.442N	0.165N
Epididymis * Exfoliated Germ Cell	Simple Incidence	1/20 (5.0%)	1/23 (4.3%)	0/18 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	1/21.9 (4.6%)	0/18.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)	0/18 (0.0%)
	Time-to-First	89 (T)	56	----
	Poly-K P-Value	0.349N	0.740N	0.521N
	Severity Profile	1 0 0 0	0 1 0 0	---
	JT/SW P-Value	0.207N	0.473N	0.239N
	RTE P-Value	0.204N	0.464N	0.204N
Preputial Gland * Inflammation	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/21.1 (9.5%)	0/18.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)	0/18 (0.0%)
	Time-to-First	----	89 (T)	----
	Poly-K P-Value	0.656	0.246	---
	Severity Profile	---	0 0 0 2	---
	JT/SW P-Value	0.466	0.091	0.241
	RTE P-Value	0.500	0.067	0.500
Preputial Gland, Duct * Ectasia	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	0/18 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/21.1 (9.5%)	0/18.0 (0.0%)
	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)	0/18 (0.0%)
	Time-to-First	----	89 (T)	----
	Poly-K P-Value	0.656	0.246	---
	Severity Profile	---	0 0 1 1	---
	JT/SW P-Value	0.466	0.091	0.241
	RTE P-Value	0.500	0.068	0.500
Prostate * Atrophy	Simple Incidence	0/20 (0.0%)	2/23 (8.7%)	1/18 (5.6%)
	Poly-K Incidence	0/20.0 (0.0%)	2/21.9 (9.1%)	1/18.0 (5.6%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	1/18 (5.6%)
	Time-to-First	----	56	85 (T)
	Poly-K P-Value	0.328	0.255	0.479
	Severity Profile	---	0 1 1 0	0 0 1 0
	JT/SW P-Value	0.198	0.091	0.180
	RTE P-Value	0.215	0.135	0.215
Prostate * Inflammation	Simple Incidence	2/20 (10.0%)	2/23 (8.7%)	2/18 (11.1%)
	Poly-K Incidence	2/20.0 (10.0%)	2/21.1 (9.5%)	2/18.0 (11.1%)
	Terminal Incidence	2/20 (10.0%)	2/20 (10.0%)	2/18 (11.1%)
	Time-to-First	90 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.563	0.676N	0.658
	Severity Profile	2 0 0 0	2 0 0 0	1 1 0 0
	JT/SW P-Value	0.439	0.558	0.510
	RTE P-Value	0.435	0.446N	0.435

Table 6: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 100K	BPA 300K
Prostate * Infiltration Cellular	Simple Incidence	17/20 (85.0%)	17/23 (73.9%)	11/18 (61.1%)
	Poly-K Incidence	17/20.0 (85.0%)	17/22.2 (76.5%)	11/18.0 (61.1%)
	Terminal Incidence	17/20 (85.0%)	15/20 (75.0%)	11/18 (61.1%)
	Time-to-First	85 (T)	73	85 (T)
	Poly-K P-Value	0.065N	0.382N	0.094N
	Severity Profile	8 7 2 0	9 6 0 2	4 5 1 1
	JT/SW P-Value	0.159N	0.213N	0.200N
	RTE P-Value	0.169N	0.229N	0.169N
Testes, Germinal Epithelium * Degeneration	Simple Incidence	1/20 (5.0%)	1/23 (4.3%)	0/18 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	1/21.9 (4.6%)	0/18.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)	0/18 (0.0%)
	Time-to-First	89 (T)	56	----
	Poly-K P-Value	0.349N	0.740N	0.521N
	Severity Profile	0 0 0 1	0 0 1 0	---
	JT/SW P-Value	0.195N	0.447N	0.229N
	RTE P-Value	0.164N	0.442N	0.164N
Testes, Seminiferous Tubule * Giant Cell	Simple Incidence	0/20 (0.0%)	0/23 (0.0%)	2/18 (11.1%)
	Poly-K Incidence	0/20.0 (0.0%)	0/21.1 (0.0%)	2/18.0 (11.1%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	2/18 (11.1%)
	Time-to-First	----	----	91 (T)
	Poly-K P-Value	0.073	---	0.210
	Severity Profile	---	---	2 0 0 0
	JT/SW P-Value	0.032 *	0.500	0.033 *
	RTE P-Value	0.042 *	0.500	0.042 *
Kidney * Cyst	Simple Incidence	9/20 (45.0%)	11/23 (47.8%)	14/18 (77.8%)
	Poly-K Incidence	9/20.0 (45.0%)	11/21.1 (52.0%)	14/18.0 (77.8%)
	Terminal Incidence	9/20 (45.0%)	11/20 (55.0%)	14/18 (77.8%)
	Time-to-First	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.027 *	0.446	0.037 *
	Severity Profile	6 3 0 0	5 5 1 0	3 8 3 0
	JT/SW P-Value	0.003 **	0.310	0.003 **
	RTE P-Value	0.002 **	0.289	0.002 **
Kidney, Cortex * Cyst	Simple Incidence	1/20 (5.0%)	0/23 (0.0%)	0/18 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/21.1 (0.0%)	0/18.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/20 (0.0%)	0/18 (0.0%)
	Time-to-First	91 (T)	----	----
	Poly-K P-Value	0.278N	0.489N	0.521N
	Severity Profile	1 0 0 0	---	---
	JT/SW P-Value	0.108N	0.142N	0.136N
	RTE P-Value	0.163N	0.163N	0.163N
Kidney, Renal Tubule * Cyst	Simple Incidence	8/20 (40.0%)	11/23 (47.8%)	14/18 (77.8%)
	Poly-K Incidence	8/20.0 (40.0%)	11/21.1 (52.0%)	14/18.0 (77.8%)
	Terminal Incidence	8/20 (40.0%)	11/20 (55.0%)	14/18 (77.8%)
	Time-to-First	86 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.012 *	0.324	0.016 *
	Severity Profile	5 3 0 0	5 5 1 0	3 8 3 0
	JT/SW P-Value	0.002 **	0.232	0.002 **
	RTE P-Value	0.001 **	0.222	0.001 **

Table 6: Effect of High Level Exposures to BPA on Non-neoplasm Incidence in Males

		Vehicle Controls	BPA 100K	BPA 300K
Kidney * Hydronephrosis	Simple Incidence	0/20 (0.0%)	3/23 (13.0%)	1/18 (5.6%)
	Poly-K Incidence	0/20.0 (0.0%)	3/22.5 (13.4%)	1/18.0 (5.6%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	1/18 (5.6%)
	Time-to-First	----	56	89 (T)
	Poly-K P-Value	0.339	0.134	0.479
	Severity Profile	---	1 0 0 2	1 0 0 0
	JT/SW P-Value	0.234	0.049 * ¹	0.136
	RTE P-Value	0.253	0.035 *	0.253
Kidney * Nephropathy	Simple Incidence	14/20 (70.0%)	22/23 (95.7%)	16/18 (88.9%)
	Poly-K Incidence	14/20.0 (70.0%)	22/23.0 (95.7%)	16/18.0 (88.9%)
	Terminal Incidence	14/20 (70.0%)	19/20 (95.0%)	16/18 (88.9%)
	Time-to-First	85 (T)	56	85 (T)
	Poly-K P-Value	0.066	0.027 *	0.152
	Severity Profile	14 0 0 0	19 2 0 1	11 5 0 0
	JT/SW P-Value	0.003 **	0.004 **	0.004 **
	RTE P-Value	0.004 **	0.006 **	0.004 **

Table 7: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Females

		Vehicle Controls	EE 0.5	EE 5.0
Heart * Cardiomyopathy	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	2/20 (10.0%)
	Time-to-First	----	85 (T)	85 (T)
	Poly-K P-Value	0.194	0.500	0.234
	Severity Profile	---	1 0 0 0	2 0 0 0
	JT/SW P-Value	0.075	0.159	0.088
	RTE P-Value	0.087	0.237	0.087
Liver * Fatty Change	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	----	85 (T)
	Poly-K P-Value	0.312	---	0.500
	Severity Profile	---	---	0 0 1 0
	JT/SW P-Value	0.110	0.500	0.131
	RTE P-Value	0.163	0.500	0.163
Liver * Fibrosis	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	----	----	89 (T)
	Poly-K P-Value	0.088	---	0.234
	Severity Profile	---	---	0 2 0 0
	JT/SW P-Value	0.040 *	0.500	0.047 *
	RTE P-Value	0.055	0.500	0.055
Liver * Granuloma	Simple Incidence	2/20 (10.0%)	3/20 (15.0%)	2/20 (10.0%)
	Poly-K Incidence	2/20.0 (10.0%)	3/20.0 (15.0%)	2/20.0 (10.0%)
	Terminal Incidence	2/20 (10.0%)	3/20 (15.0%)	2/20 (10.0%)
	Time-to-First	90 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.576N	0.500	0.696
	Severity Profile	2 0 0 0	3 0 0 0	2 0 0 0
	JT/SW P-Value	0.500	0.318	0.477
	RTE P-Value	0.439N	0.316	0.500
Pancreas, Acinar Cell * Atrophy	Simple Incidence	4/20 (20.0%)	1/20 (5.0%)	2/20 (10.0%)
	Poly-K Incidence	4/20.0 (20.0%)	1/20.0 (5.0%)	2/20.0 (10.0%)
	Terminal Incidence	4/20 (20.0%)	1/20 (5.0%)	2/20 (10.0%)
	Time-to-First	85 (T)	85 (T)	88 (T)
	Poly-K P-Value	0.392N	0.169N	0.331N
	Severity Profile	2 2 0 0	1 0 0 0	2 0 0 0
	JT/SW P-Value	0.147N	0.072N	0.116N
	RTE P-Value	0.244N	0.057N	0.120N
Pituitary Gland * Cyst	Simple Incidence	1/20 (5.0%)	2/20 (10.0%)	2/20 (10.0%)
	Poly-K Incidence	1/20.0 (5.0%)	2/20.0 (10.0%)	2/20.0 (10.0%)
	Terminal Incidence	1/20 (5.0%)	2/20 (10.0%)	2/20 (10.0%)
	Time-to-First	88 (T)	87 (T)	85 (T)
	Poly-K P-Value	0.482	0.500	0.500

Table 7: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Females

		Vehicle Controls	EE 0.5	EE 5.0
Thyroid Gland * Cyst or Ultimobranchial Cyst	Simple Incidence	6/20 (30.0%)	15/19 (78.9%)	9/20 (45.0%)
	Poly-K Incidence	6/20.0 (30.0%)	15/19.0 (78.9%)	9/20.0 (45.0%)
	Terminal Incidence	6/20 (30.0%)	15/19 (78.9%)	9/20 (45.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.554	0.001 **	0.260
Thyroid Gland * Ectopic Thymus	Simple Incidence	0/20 (0.0%)	1/19 (5.3%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/19.0 (5.3%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	1/19 (5.3%)	2/20 (10.0%)
	Time-to-First	----	89 (T)	85 (T)
	Poly-K P-Value	0.199	0.490	0.234
Mammary Gland, Duct * Hyperplasia	Simple Incidence	7/20 (35.0%)	13/20 (65.0%)	7/20 (35.0%)
	Poly-K Incidence	7/20.0 (35.0%)	13/20.0 (65.0%)	7/20.0 (35.0%)
	Terminal Incidence	7/20 (35.0%)	13/20 (65.0%)	7/20 (35.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.349N	0.053	0.627
	Severity Profile	7 0 0 0	8 5 0 0	4 3 0 0
	JT/SW P-Value	0.324	0.010 * ¹	0.107
	RTE P-Value	0.392N	0.011 *	0.336
Mammary Gland, Alveolus * Hyperplasia	Simple Incidence	6/20 (30.0%)	11/20 (55.0%)	3/20 (15.0%)
	Poly-K Incidence	6/20.0 (30.0%)	11/20.0 (55.0%)	3/20.0 (15.0%)
	Terminal Incidence	6/20 (30.0%)	11/20 (55.0%)	3/20 (15.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.069N	0.099	0.227N
	Severity Profile	5 1 0 0	7 1 3 0	3 0 0 0
	JT/SW P-Value	0.165N	0.962N	0.191N
	RTE P-Value	0.038N*	0.024 *	0.147N
Mammary Gland, Alveolus * Hyperplasia (adjusted for pseudo-pregnancy)	Simple Incidence	5/17 (29.4%)	9/18 (50.0%)	3/20 (15.0%)
	Poly-K Incidence	5/17.0 (29.4%)	9/18.0 (50.0%)	3/20.0 (15.0%)
	Terminal Incidence	5/17 (29.4%)	9/18 (50.0%)	3/20 (15.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.088N	0.186	0.257N
	Severity Profile	4 1 0 0	7 0 2 0	3 0 0 0
	JT/SW P-Value	0.129N	0.895N	0.195N
	RTE P-Value	0.052N	0.083	0.161N
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	11/20 (55.0%)	15/20 (75.0%)	10/20 (50.0%)
	Poly-K Incidence	11/20.0 (55.0%)	15/20.0 (75.0%)	10/20.0 (50.0%)
	Terminal Incidence	11/20 (55.0%)	15/20 (75.0%)	10/20 (50.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.294N	0.161	0.500N
	Severity Profile	10 1 0 0	7 5 3 0	7 3 0 0
	JT/SW P-Value	0.457	0.012 * ¹	0.147
	RTE P-Value	0.262N	0.014 *	0.464

Table 7: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Females

		Vehicle Controls	EE 0.5	EE 5.0
Mammary Gland, Duct or Alveolus * Hyperplasia (adjusted for pseudo-pregnancy)	Simple Incidence	11/19 (57.9%)	15/20 (75.0%)	10/20 (50.0%)
	Poly-K Incidence	11/19.0 (57.9%)	15/20.0 (75.0%)	10/20.0 (50.0%)
	Terminal Incidence	11/19 (57.9%)	15/20 (75.0%)	10/20 (50.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.240N	0.216	0.433N
	Severity Profile	10 1 0 0	7 5 3 0	7 3 0 0
Lymph Node, Mandibular * Hemorrhage	JT/SW P-Value	0.470N	0.983N	0.562N
	RTE P-Value	0.228N	0.017 *	0.480N
	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	----	----	86 (T)
Lymph Node, Mandibular * Hyperplasia	Poly-K P-Value	0.088	---	0.234
	Severity Profile	---	---	0 1 1 0
	JT/SW P-Value	0.040 *	0.500	0.047 *
	RTE P-Value	0.053	0.500	0.053
	Simple Incidence	0/20 (0.0%)	2/20 (10.0%)	4/20 (20.0%)
	Poly-K Incidence	0/20.0 (0.0%)	2/20.0 (10.0%)	4/20.0 (20.0%)
Ovary * Cyst	Terminal Incidence	0/20 (0.0%)	2/20 (10.0%)	4/20 (20.0%)
	Time-to-First	----	85 (T)	85 (T)
	Poly-K P-Value	0.048 *	0.234	0.051
	Severity Profile	---	0 1 1 0	0 1 3 0
	JT/SW P-Value	0.017 *	0.076	0.020 *
	RTE P-Value	0.021 *	0.152	0.021 *
Ovary, Parenchyma * Cyst	Simple Incidence	4/20 (20.0%)	17/19 (89.5%)	20/20 (100.0%)
	Poly-K Incidence	4/20.0 (20.0%)	17/19.0 (89.5%)	20/20.0 (100.0%)
	Terminal Incidence	4/20 (20.0%)	17/19 (89.5%)	20/20 (100.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	0/20 (0.0%)	1/19 (5.3%)	3/20 (15.0%)
Ovary, Corpus Luteum * Cyst	Poly-K Incidence	0/20.0 (0.0%)	1/19.0 (5.3%)	3/20.0 (15.0%)
	Terminal Incidence	0/20 (0.0%)	1/19 (5.3%)	3/20 (15.0%)
	Time-to-First	----	95 (T)	88 (T)
	Poly-K P-Value	0.073	0.490	0.111
	Severity Profile	0/20 (0.0%)	1/19 (5.3%)	0/20 (0.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/19.0 (5.3%)	0/20.0 (0.0%)
Ovary, Follicle * Cyst	Terminal Incidence	0/20 (0.0%)	1/19 (5.3%)	0/20 (0.0%)
	Time-to-First	----	85 (T)	----
	Poly-K P-Value	0.685N	0.490	---
	Severity Profile	4/20 (20.0%)	16/19 (84.2%)	19/20 (95.0%)
	Poly-K Incidence	4/20.0 (20.0%)	16/19.0 (84.2%)	19/20.0 (95.0%)
	Terminal Incidence	4/20 (20.0%)	16/19 (84.2%)	19/20 (95.0%)
Ovary, Follicle * Cyst	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	0 4 0 0	0 2 4 10	1 1 5 12
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***

Table 7: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Females

		Vehicle Controls	EE 0.5	EE 5.0
Ovary, Rete Ovarii * Cyst	Simple Incidence	1/20 (5.0%)	0/19 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	0/19.0 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	0/19 (0.0%)	0/20 (0.0%)
	Time-to-First	95 (T)	----	----
	Poly-K P-Value	0.459N	0.510N	0.500N
Ovary, Corpus Luteum * Hypertrophy	Simple Incidence	4/20 (20.0%)	2/19 (10.5%)	0/20 (0.0%)
	Poly-K Incidence	4/20.0 (20.0%)	2/19.0 (10.5%)	0/20.0 (0.0%)
	Terminal Incidence	4/20 (20.0%)	2/19 (10.5%)	0/20 (0.0%)
	Time-to-First	85 (T)	87 (T)	----
	Poly-K P-Value	0.047N*	0.356N	0.051N
Ovary * Hematocyst	Simple Incidence	0/20 (0.0%)	0/19 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/19.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	0/19 (0.0%)	2/20 (10.0%)
	Time-to-First	----	----	85 (T)
	Poly-K P-Value	0.091	---	0.234
Ovary, Corpus Luteum * Depletion	Simple Incidence	0/20 (0.0%)	17/19 (89.5%)	18/20 (90.0%)
	Poly-K Incidence	0/20.0 (0.0%)	17/19.0 (89.5%)	18/20.0 (90.0%)
	Terminal Incidence	0/20 (0.0%)	17/19 (89.5%)	18/20 (90.0%)
	Time-to-First	----	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	---	0 5 5 7	0 0 1 17
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***
Ovary, Antral Follicles * Depletion	Simple Incidence	3/20 (15.0%)	16/19 (84.2%)	19/20 (95.0%)
	Poly-K Incidence	3/20.0 (15.0%)	16/19.0 (84.2%)	19/20.0 (95.0%)
	Terminal Incidence	3/20 (15.0%)	16/19 (84.2%)	19/20 (95.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
Uterus, Endometrium * Vacuolization Cytoplasmic	Simple Incidence	3/20 (15.0%)	2/20 (10.0%)	0/20 (0.0%)
	Poly-K Incidence	3/20.0 (15.0%)	2/20.0 (10.0%)	0/20.0 (0.0%)
	Terminal Incidence	3/20 (15.0%)	2/20 (10.0%)	0/20 (0.0%)
	Time-to-First	85 (T)	87 (T)	----
	Poly-K P-Value	0.092N	0.500N	0.111N
Uterus, Endometrium * Degeneration	Simple Incidence	0/20 (0.0%)	12/20 (60.0%)	17/20 (85.0%)
	Poly-K Incidence	0/20.0 (0.0%)	12/20.0 (60.0%)	17/20.0 (85.0%)
	Terminal Incidence	0/20 (0.0%)	12/20 (60.0%)	17/20 (85.0%)
	Time-to-First	----	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	---	4 4 2 2	10 5 1 1
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***

Table 7: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Females

		Vehicle Controls	EE 0.5	EE 5.0
Uterus, Endometrium * Hyperplasia	Simple Incidence	1/20 (5.0%)	5/20 (25.0%)	5/20 (25.0%)
	Poly-K Incidence	1/20.0 (5.0%)	5/20.0 (25.0%)	5/20.0 (25.0%)
	Terminal Incidence	1/20 (5.0%)	5/20 (25.0%)	5/20 (25.0%)
	Time-to-First	88 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.154	0.089	0.089
	Severity Profile	0 1 0 0	4 1 0 0	2 3 0 0
	JT/SW P-Value	0.049 *	0.049 * ¹	0.061
	RTE P-Value	0.095	0.073	0.052
Uterus, Endometrium * Hypertrophy	Simple Incidence	0/20 (0.0%)	11/20 (55.0%)	13/20 (65.0%)
	Poly-K Incidence	0/20.0 (0.0%)	11/20.0 (55.0%)	13/20.0 (65.0%)
	Terminal Incidence	0/20 (0.0%)	11/20 (55.0%)	13/20 (65.0%)
	Time-to-First	----	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	---	0 0 8 3	0 4 3 6
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***
Uterus, Endometrium * Metaplasia	Simple Incidence	1/20 (5.0%)	11/20 (55.0%)	13/20 (65.0%)
	Poly-K Incidence	1/20.0 (5.0%)	11/20.0 (55.0%)	13/20.0 (65.0%)
	Terminal Incidence	1/20 (5.0%)	11/20 (55.0%)	13/20 (65.0%)
	Time-to-First	88 (T)	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	1 0 0 0	6 3 2 0	5 7 0 1
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***
Uterus * Infiltration Cellular	Simple Incidence	0/20 (0.0%)	17/20 (85.0%)	19/20 (95.0%)
	Poly-K Incidence	0/20.0 (0.0%)	17/20.0 (85.0%)	19/20.0 (95.0%)
	Terminal Incidence	0/20 (0.0%)	17/20 (85.0%)	19/20 (95.0%)
	Time-to-First	----	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	---	12 5 0 0	16 3 0 0
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***
Vagina, Mucocyte * Hyperplasia	Simple Incidence	3/20 (15.0%)	2/20 (10.0%)	1/20 (5.0%)
	Poly-K Incidence	3/20.0 (15.0%)	2/20.0 (10.0%)	1/20.0 (5.0%)
	Terminal Incidence	3/20 (15.0%)	2/20 (10.0%)	1/20 (5.0%)
	Time-to-First	85 (T)	87 (T)	89 (T)
	Poly-K P-Value	0.267N	0.500N	0.301N
Vagina, Mucosa * Hyperplasia	Simple Incidence	0/20 (0.0%)	15/20 (75.0%)	19/20 (95.0%)
	Poly-K Incidence	0/20.0 (0.0%)	15/20.0 (75.0%)	19/20.0 (95.0%)
	Terminal Incidence	0/20 (0.0%)	15/20 (75.0%)	19/20 (95.0%)
	Time-to-First	----	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	---	0 0 9 6	0 1 4 14
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***

Table 7: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Females

		Vehicle Controls	EE 0.5	EE 5.0
Vagina, Muscularis * Hypertrophy	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)	11/20 (55.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)	11/20.0 (55.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	11/20 (55.0%)
	Time-to-First	----	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	0.500	<.001 ***
	Severity Profile	---	0 0 1 0	0 7 4 0
	JT/SW P-Value	<.001 ***	0.159	<.001 ***
	RTE P-Value	<.001 ***	0.296	<.001 ***
Kidney, Renal Tubule * Mineralization	Simple Incidence	14/20 (70.0%)	16/20 (80.0%)	19/20 (95.0%)
	Poly-K Incidence	14/20.0 (70.0%)	16/20.0 (80.0%)	19/20.0 (95.0%)
	Terminal Incidence	14/20 (70.0%)	16/20 (80.0%)	19/20 (95.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.040 *	0.360	0.043 *
	Severity Profile	11 3 0 0	11 3 2 0	11 6 2 0
	JT/SW P-Value	0.009 **	0.154	0.009 **
	RTE P-Value	0.011 *	0.140	0.011 *
Kidney, Renal Tubule * Cyst	Simple Incidence	1/20 (5.0%)	7/20 (35.0%)	2/20 (10.0%)
	Poly-K Incidence	1/20.0 (5.0%)	7/20.0 (35.0%)	2/20.0 (10.0%)
	Terminal Incidence	1/20 (5.0%)	7/20 (35.0%)	2/20 (10.0%)
	Time-to-First	88 (T)	85 (T)	88 (T)
	Poly-K P-Value	0.486N	0.019 *	0.500
	Severity Profile	1 0 0 0	5 2 0 0	2 0 0 0
	JT/SW P-Value	0.345	0.009 ** 1	0.080
	RTE P-Value	0.349N	0.003 **	0.335
Kidney * Nephropathy	Simple Incidence	12/20 (60.0%)	12/20 (60.0%)	18/20 (90.0%)
	Poly-K Incidence	12/20.0 (60.0%)	12/20.0 (60.0%)	18/20.0 (90.0%)
	Terminal Incidence	12/20 (60.0%)	12/20 (60.0%)	18/20 (90.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.017 *	0.623	0.029 *
	Severity Profile	12 0 0 0	11 1 0 0	17 1 0 0
	JT/SW P-Value	0.017 *	0.425	0.018 *
	RTE P-Value	0.008 **	0.406	0.014 *

Table 8: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Males

		Vehicle Controls	EE 0.5	EE 5.0
Heart * Cardiomyopathy	Simple Incidence	7/20 (35.0%)	3/20 (15.0%)	9/20 (45.0%)
	Poly-K Incidence	7/20.0 (35.0%)	3/20.0 (15.0%)	9/20.0 (45.0%)
	Terminal Incidence	7/20 (35.0%)	3/20 (15.0%)	9/20 (45.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.168	0.136N	0.376
	Severity Profile	6 1 0 0	3 0 0 0	9 0 0 0
	JT/SW P-Value	0.284	0.932	0.346
	RTE P-Value	0.148	0.067N	0.287
Liver * Vacuolization Cytoplasmic	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	----	----	90 (T)
	Poly-K P-Value	0.088	---	0.234
	Severity Profile	---	---	2 0 0 0
	JT/SW P-Value	0.040 *	0.500	0.047 *
	RTE P-Value	0.056	0.500	0.056
Liver * Hepatodiaphragmatic Nodule	Simple Incidence	1/20 (5.0%)	2/20 (10.0%)	0/20 (0.0%)
	Poly-K Incidence	1/20.0 (5.0%)	2/20.0 (10.0%)	0/20.0 (0.0%)
	Terminal Incidence	1/20 (5.0%)	2/20 (10.0%)	0/20 (0.0%)
	Time-to-First	90 (T)	90 (T)	----
	Poly-K P-Value	0.302N	0.500	0.500N
	Severity Profile	4 0 0 0	3 1 0 0	2 1 1 0
Pancreas, Acinus * Degeneration	Simple Incidence	4/20 (20.0%)	4/20 (20.0%)	4/20 (20.0%)
	Poly-K Incidence	4/20.0 (20.0%)	4/20.0 (20.0%)	4/20.0 (20.0%)
	Terminal Incidence	4/20 (20.0%)	4/20 (20.0%)	4/20 (20.0%)
	Time-to-First	90 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.609	0.650	0.650
	Severity Profile	4 0 0 0	3 1 0 0	2 1 1 0
	JT/SW P-Value	0.434	0.469	0.513
	RTE P-Value	0.438	0.472	0.437
Pancreas * Inflammation	Simple Incidence	2/20 (10.0%)	1/20 (5.0%)	1/20 (5.0%)
	Poly-K Incidence	2/20.0 (10.0%)	1/20.0 (5.0%)	1/20.0 (5.0%)
	Terminal Incidence	2/20 (10.0%)	1/20 (5.0%)	1/20 (5.0%)
	Time-to-First	90 (T)	90 (T)	93 (T)
	Poly-K P-Value	0.480N	0.500N	0.500N
	Severity Profile	2 0 0 0	1 0 0 0	0 1 0 0
	JT/SW P-Value	0.281N	0.277N	0.329N
	RTE P-Value	0.330N	0.272N	0.286N
Pancreas * Infiltration Cellular	Simple Incidence	2/20 (10.0%)	2/20 (10.0%)	2/20 (10.0%)
	Poly-K Incidence	2/20.0 (10.0%)	2/20.0 (10.0%)	2/20.0 (10.0%)
	Terminal Incidence	2/20 (10.0%)	2/20 (10.0%)	2/20 (10.0%)
	Time-to-First	90 (T)	89 (T)	85 (T)
	Poly-K P-Value	0.644	0.696	0.696
	Severity Profile	2 0 0 0	2 0 0 0	2 0 0 0
	JT/SW P-Value	0.500	0.500	0.583
	RTE P-Value	0.500	0.500	0.500

Table 8: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Males

		Vehicle Controls	EE 0.5	EE 5.0
Pituitary Gland * Cyst	Simple Incidence	3/20 (15.0%)	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	3/20.0 (15.0%)	0/20.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	3/20 (15.0%)	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	85 (T)	----	85 (T)
	Poly-K P-Value	0.626N	0.111N	0.500N
Thyroid Gland * Ultimobranchial Cyst	Simple Incidence	6/20 (30.0%)	5/20 (25.0%)	4/20 (20.0%)
	Poly-K Incidence	6/20.0 (30.0%)	5/20.0 (25.0%)	4/20.0 (20.0%)
	Terminal Incidence	6/20 (30.0%)	5/20 (25.0%)	4/20 (20.0%)
	Time-to-First	89 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.334N	0.500N	0.360N
Mammary Gland, Duct * Hyperplasia	Simple Incidence	0/20 (0.0%)	5/20 (25.0%)	14/20 (70.0%)
	Poly-K Incidence	0/20.0 (0.0%)	5/20.0 (25.0%)	14/20.0 (70.0%)
	Terminal Incidence	0/20 (0.0%)	5/20 (25.0%)	14/20 (70.0%)
	Time-to-First	----	89 (T)	85 (T)
	Poly-K P-Value	<.001 ***	0.022 *	<.001 ***
	Severity Profile	---	3 2 0 0	3 4 5 2
	JT/SW P-Value	<.001 ***	0.009 **	<.001 ***
	RTE P-Value	<.001 ***	0.035 *	<.001 ***
Mammary Gland, Alveolus * Hyperplasia	Simple Incidence	5/20 (25.0%)	14/20 (70.0%)	13/20 (65.0%)
	Poly-K Incidence	5/20.0 (25.0%)	14/20.0 (70.0%)	13/20.0 (65.0%)
	Terminal Incidence	5/20 (25.0%)	14/20 (70.0%)	13/20 (65.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.035 *	0.003 **	0.009 **
	Severity Profile	4 1 0 0	5 5 3 1	1 3 4 5
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	0.002 **	<.001 ***
Mammary Gland, Duct or Alveolus * Hyperplasia	Simple Incidence	5/20 (25.0%)	16/20 (80.0%)	20/20 (100.0%)
	Poly-K Incidence	5/20.0 (25.0%)	16/20.0 (80.0%)	20/20.0 (100.0%)
	Terminal Incidence	5/20 (25.0%)	16/20 (80.0%)	20/20 (100.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	<.001 ***	<.001 ***	<.001 ***
	Severity Profile	4 1 0 0	5 7 3 1	1 3 9 7
	JT/SW P-Value	<.001 ***	<.001 ***	<.001 ***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***
Lymph Node, Mandibular * Hyperplasia	Simple Incidence	2/20 (10.0%)	0/20 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	2/20.0 (10.0%)	0/20.0 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	2/20 (10.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	89 (T)	----	----
	Poly-K P-Value	0.217N	0.234N	0.234N
	Severity Profile	0 1 0 1	---	---
	JT/SW P-Value	0.040N*	0.076N	0.047N*
	RTE P-Value	0.054N	0.054N	0.054N

Table 8: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Males

		Vehicle Controls	EE 0.5	EE 5.0
Coagulating Gland, Epithelium * Hyperplasia	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	6/20 (30.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	6/20.0 (30.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	6/20 (30.0%)
	Time-to-First	----	----	85 (T)
	Poly-K P-Value	<.001 ***	---	0.009 **
	Severity Profile	---	---	0 5 1 0
Epididymis * Hypospermia	JT/SW P-Value	<.001 ***	0.500	<.001 ***
	RTE P-Value	<.001 ***	0.500	<.001 ***
	Simple Incidence	1/20 (5.0%)	2/20 (10.0%)	7/20 (35.0%)
	Poly-K Incidence	1/20.0 (5.0%)	2/20.0 (10.0%)	7/20.0 (35.0%)
	Terminal Incidence	1/20 (5.0%)	2/20 (10.0%)	7/20 (35.0%)
	Time-to-First	89 (T)	86 (T)	85 (T)
Epididymis * Infiltration Cellular	Poly-K P-Value	0.006 **	0.500	0.019 *
	Severity Profile	0 0 0 1	0 0 0 2	0 4 0 3
	JT/SW P-Value	0.008 **	0.277	0.009 **
	RTE P-Value	0.007 **	0.322	0.008 **
	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	2/20.0 (10.0%)
Epididymis * Exfoliated Germ Cell	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	----	----	89 (T)
	Poly-K P-Value	0.088	---	0.234
	Severity Profile	---	---	2 0 0 0
	JT/SW P-Value	0.040 *	0.500	0.047 *
	RTE P-Value	0.054	0.500	0.054
Epididymis * Exfoliated Germ Cell	Simple Incidence	1/20 (5.0%)	2/20 (10.0%)	6/20 (30.0%)
	Poly-K Incidence	1/20.0 (5.0%)	2/20.0 (10.0%)	6/20.0 (30.0%)
	Terminal Incidence	1/20 (5.0%)	2/20 (10.0%)	6/20 (30.0%)
	Time-to-First	89 (T)	86 (T)	85 (T)
	Poly-K P-Value	0.019 *	0.500	0.043 *
	Severity Profile	1 0 0 0	2 0 0 0	3 3 0 0
Preputial Gland * Inflammation	JT/SW P-Value	0.011 *	0.277	0.013 *
	RTE P-Value	0.008 **	0.334	0.007 **
	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	----	89 (T)
Preputial Gland, Duct * Ectasia	Poly-K P-Value	0.312	---	0.500
	Severity Profile	---	---	0 0 0 1
	JT/SW P-Value	0.110	0.500	0.131
	RTE P-Value	0.169	0.500	0.169
	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	1/20.0 (5.0%)
Preputial Gland, Duct * Ectasia	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	1/20 (5.0%)
	Time-to-First	----	----	89 (T)
	Poly-K P-Value	0.312	---	0.500
	Severity Profile	---	---	0 0 0 1
	JT/SW P-Value	0.110	0.500	0.131
	RTE P-Value	0.167	0.500	0.167

Table 8: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Males

		Vehicle Controls	EE 0.5	EE 5.0
Preputial Gland * Infiltration Cellular	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	----	----	85 (T)
	Poly-K P-Value	0.088	---	0.234
	Severity Profile	---	---	1 1 0 0
	JT/SW P-Value	0.040 *	0.500	0.047 *
	RTE P-Value	0.053	0.500	0.053
Prostate * Atrophy	Simple Incidence	0/20 (0.0%)	1/20 (5.0%)	1/20 (5.0%)
	Poly-K Incidence	0/20.0 (0.0%)	1/20.0 (5.0%)	1/20.0 (5.0%)
	Terminal Incidence	0/20 (0.0%)	1/20 (5.0%)	1/20 (5.0%)
	Time-to-First	----	86 (T)	85 (T)
	Poly-K P-Value	0.472	0.500	0.500
	Severity Profile	---	0 1 0 0	0 0 0 1
	JT/SW P-Value	0.185	0.159	0.224
	RTE P-Value	0.166	0.278	0.166
Prostate * Inflammation	Simple Incidence	2/20 (10.0%)	1/20 (5.0%)	1/20 (5.0%)
	Poly-K Incidence	2/20.0 (10.0%)	1/20.0 (5.0%)	1/20.0 (5.0%)
	Terminal Incidence	2/20 (10.0%)	1/20 (5.0%)	1/20 (5.0%)
	Time-to-First	90 (T)	90 (T)	90 (T)
	Poly-K P-Value	0.480N	0.500N	0.500N
	Severity Profile	2 0 0 0	1 0 0 0	1 0 0 0
	JT/SW P-Value	0.265N	0.277N	0.316N
	RTE P-Value	0.311N	0.269N	0.269N
Prostate * Infiltration Cellular	Simple Incidence	17/20 (85.0%)	17/20 (85.0%)	12/20 (60.0%)
	Poly-K Incidence	17/20.0 (85.0%)	17/20.0 (85.0%)	12/20.0 (60.0%)
	Terminal Incidence	17/20 (85.0%)	17/20 (85.0%)	12/20 (60.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.032N*	0.667	0.075N
	Severity Profile	8 7 2 0	7 9 1 0	4 6 2 0
	JT/SW P-Value	0.166N	0.534N	0.195N
	RTE P-Value	0.137N	0.474	0.167N
Seminal Vesicle * Atrophy	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	3/20 (15.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	3/20.0 (15.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	3/20 (15.0%)
	Time-to-First	----	----	85 (T)
	Poly-K P-Value	0.024 *	---	0.111
	Severity Profile	---	---	0 2 0 1
	JT/SW P-Value	0.015 *	0.500	0.017 *
	RTE P-Value	0.016 *	0.500	0.016 *
Testes, Germinal Epithelium * Degeneration	Simple Incidence	1/20 (5.0%)	2/20 (10.0%)	9/20 (45.0%)
	Poly-K Incidence	1/20.0 (5.0%)	2/20.0 (10.0%)	9/20.0 (45.0%)
	Terminal Incidence	1/20 (5.0%)	2/20 (10.0%)	9/20 (45.0%)
	Time-to-First	89 (T)	86 (T)	85 (T)
	Poly-K P-Value	<.001 ***	0.500	0.002 **
	Severity Profile	0 0 0 1	0 0 0 2	2 2 1 4
	JT/SW P-Value	0.001 **	0.277	0.002 **
	RTE P-Value	0.002 **	0.325	0.002 **

Table 8: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Males

		Vehicle Controls	EE 0.5	EE 5.0
Testes, Seminiferous Tubule * Giant Cell	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	2/20.0 (10.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	2/20 (10.0%)
	Time-to-First	----	----	89 (T)
	Poly-K P-Value	0.088	---	0.234
	Severity Profile	---	---	2 0 0 0
	JT/SW P-Value	0.040 *	0.500	0.047 *
	RTE P-Value	0.055	0.500	0.055
Kidney, Renal Tubule * Mineralization	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	6/20 (30.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	6/20.0 (30.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	6/20 (30.0%)
	Time-to-First	----	----	85 (T)
	Poly-K P-Value	<.001 ***	---	0.009 **
	Severity Profile	---	---	5 1 0 0
	JT/SW P-Value	<.001 ***	0.500	<.001 ***
	RTE P-Value	<.001 ***	0.500	<.001 ***
Kidney * Cyst	Simple Incidence	9/20 (45.0%)	1/20 (5.0%)	2/20 (10.0%)
	Poly-K Incidence	9/20.0 (45.0%)	1/20.0 (5.0%)	2/20.0 (10.0%)
	Terminal Incidence	9/20 (45.0%)	1/20 (5.0%)	2/20 (10.0%)
	Time-to-First	86 (T)	90 (T)	91 (T)
	Poly-K P-Value	0.025N*	0.002N**	0.012N*
	Severity Profile	6 3 0 0	0 1 0 0	2 0 0 0
	JT/SW P-Value	0.003N**	0.003N**	0.002N**
	RTE P-Value	0.011N*	<.001N***	0.002N**
Kidney, Cortex * Cyst	Simple Incidence	1/20 (5.0%)	1/20 (5.0%)	2/20 (10.0%)
	Poly-K Incidence	1/20.0 (5.0%)	1/20.0 (5.0%)	2/20.0 (10.0%)
	Terminal Incidence	1/20 (5.0%)	1/20 (5.0%)	2/20 (10.0%)
	Time-to-First	91 (T)	90 (T)	91 (T)
	Poly-K P-Value	0.402	0.760	0.500
	Severity Profile	1 0 0 0	0 1 0 0	2 0 0 0
	JT/SW P-Value	0.270	0.486	0.321
	RTE P-Value	0.253	0.484	0.272
Kidney, Renal Tubule * Cyst	Simple Incidence	8/20 (40.0%)	0/20 (0.0%)	0/20 (0.0%)
	Poly-K Incidence	8/20.0 (40.0%)	0/20.0 (0.0%)	0/20.0 (0.0%)
	Terminal Incidence	8/20 (40.0%)	0/20 (0.0%)	0/20 (0.0%)
	Time-to-First	86 (T)	----	----
	Poly-K P-Value	<.001N***	<.001N***	<.001N***
	Severity Profile	5 3 0 0	---	---
	JT/SW P-Value	<.001N***	<.001N***	<.001N***
	RTE P-Value	<.001 ***	<.001 ***	<.001 ***
Kidney, Renal Tubule * Dilatation	Simple Incidence	0/20 (0.0%)	4/20 (20.0%)	7/20 (35.0%)
	Poly-K Incidence	0/20.0 (0.0%)	4/20.0 (20.0%)	7/20.0 (35.0%)
	Terminal Incidence	0/20 (0.0%)	4/20 (20.0%)	7/20 (35.0%)
	Time-to-First	----	86 (T)	85 (T)
	Poly-K P-Value	0.006 **	0.051	0.003 **
	Severity Profile	---	0 4 0 0	5 1 1 0
	JT/SW P-Value	0.004 **	0.019 *	0.004 **
	RTE P-Value	0.007 **	0.036 *	0.003 **

Table 8: Effect of Ethinyl Estradiol Exposures on Non-neoplasm Incidence in Males

		Vehicle Controls	EE 0.5	EE 5.0
Kidney * Hydronephrosis	Simple Incidence	0/20 (0.0%)	0/20 (0.0%)	4/20 (20.0%)
	Poly-K Incidence	0/20.0 (0.0%)	0/20.0 (0.0%)	4/20.0 (20.0%)
	Terminal Incidence	0/20 (0.0%)	0/20 (0.0%)	4/20 (20.0%)
	Time-to-First	----	----	85 (T)
	Poly-K P-Value	0.006 **	---	0.051
	Severity Profile	---	---	1 1 2 0
	JT/SW P-Value	0.006 **	0.500	0.007 **
Kidney * Nephropathy	RTE P-Value	0.006 **	0.500	0.006 **
	Simple Incidence	14/20 (70.0%)	16/20 (80.0%)	16/20 (80.0%)
	Poly-K Incidence	14/20.0 (70.0%)	16/20.0 (80.0%)	16/20.0 (80.0%)
	Terminal Incidence	14/20 (70.0%)	16/20 (80.0%)	16/20 (80.0%)
	Time-to-First	85 (T)	85 (T)	85 (T)
	Poly-K P-Value	0.373	0.360	0.360
	Severity Profile	14 0 0 0	12 4 0 0	15 1 0 0
	JT/SW P-Value	0.198	0.062	0.126
	RTE P-Value	0.327	0.050	0.191